the 7th annual meeting of the middle-eastern association for cancer...
TRANSCRIPT
Gaziantep University
Under the patronage of the Rector Prof. Ali Gür
21st and 22nd of December 2017
The 7th Annual Meeting of the
Middle-Eastern Association for
Cancer Research
Cancer Research from Basic Science to Clinic
Welcome Message from The President
of the 7th Annual Meeting of the MEACR
Dear colleagues,
Welcome to the 7th Annual Meeting of the MEACR in Gaziantep, Turkey. Our
colleagues from many countries participated in this conference, and I’m sure this
will be a successful event particularly with the number of oral presentations and
posters, that will be available at the meeting.
I believe that this meeting will provide a good opportunity for cooperation
between the various units of the University of Gaziantep and our colleagues
from universities worldwide, including Qatar University and the its college of
medicine. Particularly, given the obvious need for cooperation in the Middle East
region, I am happy to welcome you all in Gaziantep, the city that boasts with its
5,000 years of history. Our city is well known for its historical sites, rich cuisine
and hospitality that will make you leave with very nice memories.
The University of Gaziantep, Faculty of Medicine, is one of the pioneering
universities in national and international platforms in education, research and
health services. Our Faculty of Medicine has 1700 students with 220
international students from 45 countries and we are one of the medical faculties
that has the highest number of international students. There are two 1,000-bed
capacity hospitals that are affiliated with the Faculty of Medicine of the
University of Gaziantep. It is an institution where all kinds of surgical procedures
and diagnostic procedures are performed. Organ and bone marrow
transplantation are routinely done. With such academic work and publications,
our university is in the front lines of international rankings.
Welcome and wish you a successful meeting.
Prof. Dr. Y. Zeki ÇELEN
President of the 7th Annual Meeting of the MEACR
Dean of the Faculty of Medicine
The University of Gaziantep
Welcome Message from the MEACR
Executive Committee
Dear Colleagues and Friends, we meet once again at Gaziantep University that
has agreed so generously to host our meeting for the second time. And for
that, they have our deepest appreciation and gratitude. As a non-profit
scientific association that aims to build bridges in the Middle East to enhance
medical research and collaboration, we find our task burdened with political
complications in this area. Which made organizing the meeting this year
particularly challenging, but here we are. For more information about our
association please refer to our website: www.meacr.org.
We have so many people to thank for the realization of this event, mostly
Gaziantep University and its Rector, Prof. Ali Gür; the Faculty of Medicine of
Gaziantep University and its Dean, Prof. Yusuf Zeki Çelen and the dedicated
organizing committee, Mrs. Nur Incetahtaci, Dr. Ramazan Bal and Mrs. Amal
Kassab who have worked tirelessly and under a tight timetable to realize this
event. Of course, we also value the continuous support of Qatar University,
and its College of Medicine, particularly the VP and Dean of the College of
Medicine, Prof. Egon Toft.
On a final note, all the abstracts presented in this meeting can be published as
a full paper in the CCIJ: www.ccij-online.org. The CCIJ is preparing its 6th
Volume in 2018, and we like to invite you all to submit your next paper in its
upcoming issue, specially that with the support of the College of Medicine of
Qatar University, we are now able to provide once more a free and open access
journal for all researchers. We are grateful for all our reviewers and authors
who have already participated in the success of our past issues through their
participation and collaboration.
Thank you again for your support and participation in the 7th annual meeting of
the MEACR,
Ala-Eddin Al Mosutafa CEO of the Middle Eastern Association for Cancer Research
Editor in Chief of the Clinical Cancer Investigation Journal
Prof. College of Medicine, Qatar University
Associate member of the Biomedical Research Center of Qatar University
Organizing Committee
Honorary President: Prof. Dr. Ali Gür Gaziantep University, Gaziantep, Turkey Al Moustafa A-E MEACR & Qatar University, Doha, Qatar Kassab A Concordia University, Canada Çelen, Y.Z Gaziantep University, Gaziantep, Turkey Demirel C Gaziantep University, Gaziantep, Turkey Sucu M.M Gaziantep University, Gaziantep, Turkey Elmahli W Gaziantep University, Gaziantep, Turkey Bal R, Gaziantep University, Gaziantep, Turkey Taşdemir D Gaziantep University, Gaziantep, Turkey Zengin S Gaziantep University, Gaziantep, Turkey Elboğa U Gaziantep University, Gaziantep, Turkey
Scientific Committee
National
• Akil N, Turkey
• Bal R, Turkey
• Başkonuş İ, Turkey
• Bozdağ Z, Turkey
• Çelen Y.Z, Turkey
• Demirel C, Turkey
• Elboğa U, Turkey
• Erturhan S, Turkey
• Gokalp A, Turkey
• Gülşen M.T, Turkey
• Işık A.F, Turkey
• Sucu M. M, Turkey
International
• Aboussekhra A, SA
• Alachkar A, USA
• Alali F Q, Qatar
• Alaoui-Jamali M, Canada
• Alkhalaf M, Kuwait
• Al-Kuraya Kh, KSA
• Alsbeih G, SA
• Boudjelal M, KSA
• Chouaib S, France
• Dermime S, Qatar
• Desprez P-Y, USA
• Gali-Muhtasib H, Lebanon
• Gargouri R, Tunisia
• Khan H, USA
• Machaca Kh, Qatar
• Mraiche F, Qatar
• Pervez Sh, Pakistan
• Rabbani Sh,Canada
Day 1 : December 21, 2017 08:30 - 09:30 Registration
09:30 – 10:00 Official Opening
Keynote Speakers
Session Chairs: Dr. Hiba Bawadi & Dr. Ramazan Bal
10:00 – 10:30 Saghir Akhtar Doha, Qatar
EGFR signalling: From cancer to diabetes-induced vascular dysfunction
10:30-11 :00 Abbas Iqbal Lahore, Pakistan
New directions and advances in management of Hepatocellular cancer, Future with safety and hope
11:00 – 11:30 Coffee break- poster visit
11:30 - 12:30 Satellite Symposium: Nuclear Medicine
Session Chair: Dr. Hale Çolakoğlu Er & Dr. Elzem Şen
11:30-12:00 Sakıp Erturhan Gaziantep, Turkey
Therapeutic approach in Metastatic Prostate Cancer: Urological view-
12:00-12:30 Umut Elboga Gaziantep, Turkey
A new paradigm: Theranostic Applications in Metastatic Prostate Cancer
12:30 - 13:30 Lunch
Basic Research
Session Chairs: Dr. Saghir Akhtar & Dr. Abbas Iqbal
13:30 – 13:45 Abolfazl Movafagh Tehran, Iran
Breast Cancer Registry in Iran
13:45 – 14:00 Fatima Mraiche Doha, Qatar
Inhibition of p90 ribosomal s6 kinase potentiates cisplatin induced apoptosis, cell cycle arrest and anti-metastasis in human lung adenocarcinoma
14:00 – 14:15 Muhammad Safdar Lahore, Pakistan
Novel Relationship between 3'UTR region of EGFRs and miR-4533 genes with SNPs in Colorectal Cancer: In Silico and in Vivo
14:15 – 14:30 Ajaz Bhat Doha, Qatar
Curcumin regulates proliferation, autophagy, apoptosis and modulates intestinal barrier function in human colorectal cancer cells
14:30 – 14:45 Zehra Bozdağ Gaziantep, Turkey
The Evaluation of Satb2 Expression In Primary Epithelial And Metastatic Tumors Oh The Ovary
14:45 – 15:30 Coffee Break- poster visit
Translational Medicine
Session Chairs: Shamal Abdulah Al_Muffti & Dr. Fatima Mraiche
15:30 – 15:45 Wassim Almahli Gaziantep, Turkey
The Evaluation of Cd117 (C-Kit) Expression in Liposarcomas
15:45 – 16:00 Hiba Bawadi Doha, Qatar
Preventive and etiological role of nutrition in Oral and Pharyngeal Cancers
16:00 – 16:15 Hamid Yahya Husain Baghdad, Iraq
Top 10 cancers Incidence Rates, Pattern and Time Trends of among Iraqi Population for the last two Decades, Population and Hospital Based Registry
16:15 – 16:30 Basem Rajab Istanbul, Turkey
A Possible Prognostic Significance Of Tim1 Gene Variant In Laryngeal Cancer
16:30 – 16:45 Houda Drissi Casablanca, Morocco
Breast cancer and hormonal profile about 305 cases collected at the Mohamed IV center for the treatment of cancers in Casablanca
Day 2 : December 22, 2017
Clinical Research
Session Chairs: Dr. Abolfazl Movafagh & Dr. Moussa Alkhalaf
09:00 – 09:15 Zoubida Zaidi Setif, Algeria
Trends in cervical cancer survival in Arab World, 1990-2009
09:15 – 09:30 Omar Nimri Amman, Jordan
Bladder Cancer, 2005-2010 data. (Four MECC Countries, Jordan, Turkey, Israel and Cyprus)
09:30 – 09:45 Hadeel M. Fayyadh Fallujah, Iraq
Serological and molecular detection of humanherpes virus type 6 infection in Iraqi patients with acute and chronic lymphocytic leukemia
09:45 – 10:00 Fatima Ezzahra Imad Casablanca, Morocco
Colorectal Cancer In Patients Younger Than 40 Years: Experience Of The Mohamed Iv Center For The Treatment Of Cancer
10:00 – 10:15 Feras Alali Doha, Qatar
7-O-Methylpunctatin: A Homoisoflavonoid Scaffold with Antimetastatic Potential against MDA-MB-231 Breast Cancer Cells
10:15 – 10:45 Coffee Break- poster visit
Basic Research
Session Chairs: Dr.Zehra Bozdak & Dr. Hamid Yahya Husain
10:45 – 11:00 Moussa Alkhalaf Kuwait, Kuwait
How valuable is BRCA1 evaluation? Mutations pattern in Kuwaiti breast cancer patients
11:00 – 11:15 Mohamed Nizar Akil Gaziantep, Turkey
The role and clinical impact of genetic in breast cancer
11:15 – 11:30 Elif İşbilen Gaziantep, Turkey
Prognostic Roles of B-Cell Lymphoma 2 (Bcl-2) Expression in Breast Cancer
11:30 – 11:45 Ali Pamuk Gaziantep, Turkey
Expression And Purification Of Recombinant Active Tet Enzyme In E.Coli
11:45 – 12:00 Anas Azzam Ashour Doha, Qatar
Water-Pipe Smoking and Women’s Health: from pregnancy to breast cancer
12:00 - 13:30 Lunch
Clinical and Basic Research
Session Chairs: Dr. Ahmad Ibrahim & Dr. Waleed Arafat
13:30 – 13:45 Elzem Sen Gaziantep, Turkey
Four-Year Experience Of Pancreaticoduodenectomy At Gaziantep University Medical Faculty Hospital
13:45 – 14:00 Gulcin Elboga Gaziantep, Turkey
Anxiety, Depression in Carcinoma of Unknown Primary Patients Undergoing F-18 FDG PET-CT Imaging Procedure
14:00 – 14:15 Neslihan Bayramoğlu Tepe Gaziantep, Turkey
Determination of The Expression Levels Of Mirna 204-5p, Mirna 138-5p And Mirna 133-3p In Formaline Fixed Paraffine Embedded Tissue Samples Of Endometrial Cancer And
Relationship With The Prognosis
14:15 – 14:30 Yaman AlAhmad Doha, Qatar
Role of cell phone radiofrequency in head and neck cancer progression
14:30 – 14:45 Ala-Eddin Al Moustafa Doha, Qatar
Src/Abl tyrosine kinase inhibitor is a promising molecule for human papillomavirus-positive cervical cancer therapy
14:45 – 15:30
Coffee Break- poster visit
Basic Research
Session Chairs: Dr. Mir Faeq Ali Quadri & Dr. Ala-Eddin Al Moustafa
15:30 – 15:45 Waleed Arafat Alexandria, Egypt
A novel predictive marker of resistance to neoadjuvant Chemor adiotherapy in young Rectal Cancer patients
15:45 – 16:00 Havva Yeşil Çınkır Gaziantep, Turkey
The Role of GA-68 PSMA PET / CT in Evaluating Response to Docetaxel Therapy in Castration Resistant Prostate Cancer Patients
16:00 – 16:15 Ahmad H. Ibrahim Zakho, Iraq
Neuroprotective efficacy of Cocos nucifera Oil on Mammalian Cells after Serum Deprivation Chemotactic Grading Oxidative Stress in The Hypoxia and Ischemia
Ailments
16:15 – 16:30 Hale Çolakoğlu Er Gaziantep, Turkey
Efficacy of 64 detector computed tomography for the preoperative staging and resectability evaluation of pancreatic premalignant and malignant masses
16:30 – 16:45 Murat Karaoglan Gaziantep, Turkey
From hyperglycemia to hypoglycemia: A Case of Children with Nesidioblastosis
16:45 – 17:00 Shamal Abdulah Al_Muffti Duhok, Iraq
The Impact of Antiapoptotic and Angiogenesis activity of Fermented Virgin Coconut Oil (FVCO) as protecting Agent for neurodegeneration disease
THE 7TH ANNUAL MEETING OF THE MEACR – GAZIANTEP. TURKEY 1
ORAL PRESENTATIONS: DAY 1 21 December 2017: Gaziantep University, Turkey
Session Chairs: Dr. Hiba Bawadi and Dr. Ramazan Bal
10:00 – 10:30 Prof. Saghir Akhtar College of Medicine, Qatar University, Qatar
Saghir Akhtar is currently Professor of Pharmacology at the College of Medicine, Qatar University and Editor-in-Chief of the Journal of Drug Targeting. He was previously Professor and Director for the Centre for Genome-based Therapeutics, Cardiff University (UK) and more recently as Professor of Molecular Pharmacology at the Faculty of Medicine, Kuwait University.
Prof Akhtar holds a First class BSC (hons) degree in Pharmacy (Leicester School of Pharmacy, UK) and a PhD from the University of Bath (UK). After a post-doctoral fellowship at the University of North Carolina Medical School at Chapel Hill (USA), he began his independent academic career at Aston University (UK). He was also a visiting fellow at Oxford University (with Professor Ed Southern in the Department of Biochemistry) and later a Chairman of the Department of Pharmaceutics at Kuwait University. He has published extensively, and his multidisciplinary research has been internationally recognized by the award of several prestigious prizes including the CRS Young Investigator Research Achievement Award (USA), the Lilly Prize, the Pfizer Academic Award, (UK) and the British Pharmaceutical Conference Science Medal.
EGFR signalling: From cancer to diabetes-induced vascular
dysfunction
The four-membered EGFR/ErbB family of receptor tyrosine kinases, namely EGFR (also known as ErbB1), ErbB2, ErbB3 and ErbB4, are important signal relays for diverse pathways and regulate important functions such as cellular proliferation, motility, differentiation, invasiveness and apoptosis. Dysregulated signaling via EGFR/ErbB receptors is known to lead to the development of several cancers including malignant gliomas but there is now emerging evidence for their importance in other pathologies including diabetes-induced cardiovascular complications. In this presentation, I will review our own research on the development of targeted gene silencing strategies for inhibiting EGFR overexpression in glioblastomas and the role of ErbBs in mediating diabetes-induced vascular dysfunction. I will also present microarray-based gene expression profiling studies and proteomic data showing that overexpression and hyperphosphorylation of EGFR, and other ErbBs, in the diabetic vasculature are key early events leading to the development of diabetes-induced vascular complications. Blockade of ErbB signaling pathways with specific inhibitors prevented diabetes-induced vascular pathology in animal models of diabetes. Thus, these data suggest that strategies targeting the inhibition of EGFR/ErbB signaling that are already useful in cancer chemotherapy might also be useful for diabetes-induced vascular complications.
THE 7TH ANNUAL MEETING OF THE MEACR – GAZIANTEP. TURKEY 2
10:30 – 11:00 Dr. Abbas Iqbal Zainab Memorial Hospital, Lahore, Pakistan
New directions and advances in management of
Hepatocellular cancer, Future with safety and hope. Iqbal.A, Hassan.N, Batool.S, Abbas.Y, Kamel.E,
Hepatocellular carcinoma (HCC) is the leading cause of death in cirrhotic patients and the
third cause of cancer related deaths. Most HCCs are associated with well-known underlying
risk factors, in fact, HCC arise in cirrhotic patients in up to 90% of the cases, mainly due to
chronic viral hepatitis and alcohol abuse. Worldwide prevention strategies are put to avoid
the infection of new subjects and to minimize the risk of liver disease progression in infected
patients. HCC is a condition which lends itself to surveillance as at-risk individuals can readily
be identified. The American and European guidelines recommended implementation of
surveillance programs with ultrasound every six months in patient at-risk for developing
HCC. The diagnosis of HCC can be based on non-invasive criteria (only in cirrhotic patient) or
pathology. Accurately staging patients is essential to oncology practice. The ideal tumour
staging system in HCC needs to account for both tumor characteristics and liver function.
Treatment allocation is based on several factors: Liver function, size and number of tumors,
macro-vascular invasion or extra hepatic spread. The recommendations in terms of selection
for different treatment strategies must be made on evidence-based data. Resection, liver
transplant and interventional radiology treatment are mainstays of HCC therapy and achieve
the best outcomes in well-selected candidates. Chemoembolization is the most widely used
treatment for unresectable HCC or progression after curative treatment. Finally, in patients
with advanced HCC with preserved liver function, sorafenib is the only approved systemic
drug that has demonstrated a survival benefit and is the standard of care in this group of
patients. But after sorafenib failure so far no 2nd line systematic therapy is available till the
discovery of these novel molecules and the roads ends with darkness, but in medical science
after the each end it start new era of discoveries and we pleased to announce that at least
we able to discover and restore some further hope with safety and quality of life in form of
B.M molecules for these selected end stage patients.
Keywords: Hepatocellular carcinoma, Surveillance, Staging system, Radiofrequency ablation, Liver surgery, Liver
transplant, Transarterial chemoembolization, TKIs, B.M molecules.
Session Chairs: Dr. Hale Çolakoğlu Er & Dr. Elzem Şen
Therapeutic approach in Metastatic Prostate Cancer: Urological view Prof. Sakıp Erturhan: Gaziantep Univesrity, Turkey
A new paradigm: Theranostic Applications in Metastatic Prostate Cancer Prof. Umut Elboga: Gaziantep University, Turkey
THE 7TH ANNUAL MEETING OF THE MEACR – GAZIANTEP. TURKEY 3
Session Chairs: Dr. Saghir Akhtar & Dr. Abbas Iqbal
13:30 – 13:45 Prof. Abolfazl Movafagh Shahid Beheshti University, Tehran, Iran
Dr Abolfazl Movafagh PhD, is a distinguished professor and founder of the Department of Medical Genetics, in the School of Medicine, the second top University of Shahid Beheshti Medical University and Sciences, Tehran, Iran. He did his post doc in gene therapy at Tohoko University (2007-2008). His research interests reside in the field of leukemia and breast cancer. He is the lead investigator of several research projects for Msc and PhD students in the field of medical Genetics and cancers. He was presented with a distinguished professor award by the administration of Shahid Beheshti Medical University officials (2009). He was also awarded a national research fellow 3rd rank by Taberesy organization in Iran. He has more than 123 Pubmed or and ISI published papers and also 15 published Persian papers. He has translated/ written 15 international books in the field of medical genetics and cancers. He has delivered several oral presentations/guest lecturer in national and international conferences. He has teaching experience for medical, Msc, PhD student in the area of breast cancer, leukemia, medical genetics, syndrome, for more than 24 years. He is an editorial board member of 6 national and international journals. He was recently invited as guest leader editor for especial edition in the international Journal of Hindawi.
Breast Cancer Registry in Iran Movafagh Abolfazl1, M. Barez MR2, Maryam Hajiseyed Jadadi1 1 Department of Medical Genetics, School of Medicine, Shahid Beheshti University of Medical Sciences, Tehran, Iran. 2Cell and Molecular Biology Research Center, Department of Anatomy and Biology, Faculty of Medicine, Shahid Beheshti University, Tehran, Iran *Corresponding author: Department of Medical Genetics, Cancer Research Center, Shohada Referral Hospital, School of Medicine, Shahid Beheshti University of Medical Sciences, Tehran, Iran. [email protected]
Cancer registry has an important role for research and the monitoring of cancer status in a country’s public health. The Second main cause of death in Iran is cancer. In ten malignancies of females in Iran during 2009-2010, breast cancer has stood at the top of the list. The first official registry of cancer in Iran was launched in Babol in 1976 after increasing reports about the prevalence of esophageal cancer. In 1984 the Parliament passed a bill mandating the report of all tissues "diagnosed or suspected as cancer tissue" to the Ministry of Health. According to the ICD-O-3 published in 2013, during ten years’ cancer registry found 52068 patients with breast cancer. 97.1% of these cases were female. Breast cancer was the first type of all cancers in Iranian females by 24.6%. Most of these cases were recorded as invasive tumors. The average annual crude incidence of primary breast cancer in females was 22.6 (95%CI 22.1–23.1) per 100,000 females which is lower than in low-middle-income neighboring countries. In Iran, breast cancer is amongst the five most common cancers and ranks first among cancers diagnosed in women. Studies from Iran suggest that breast cancer affects Iranian women at least one decade younger than women in developing countries, with the mean age ranging from 47.1 to 48.8 years. Until recently, Middle East and Asian countries had the lowest rates of breast cancer in the world, but the incidence has increased rapidly during the past two decades. Causes of the rapidly increasing incidence of breast cancer in Middle East and Asian countries are incompletely understood. With an estimated
THE 7TH ANNUAL MEETING OF THE MEACR – GAZIANTEP. TURKEY 4
1.4 to 1.6 million new cases diagnosed around the world in 2008, breast cancer is the most common cancer among women in high-and middle-income, but also in a growing number of low-income countries. According to the another study of breast cancer study of A. Sadjadi et al the age-standardized incidence rate (ASR) was 16.2 per 100 000 person/year. In contrast to more developed countries, the ASR of breast cancer was low, with the lowest rate seen in Ardabil province (Iran). The estimated mortality rate for cancer in Iran was 41.1 and 65 per 100 000 for females and males in 2004. The NCR data registry of breast cancer is not exact in monitoring the effect of screening programs or showing the current status of breast cancer in Iran. A quality breast cancer registry and a screening program for breast cancer are both needed.
Key Words: Breast Cancer, Incidence, Cancer Registry, Iran Cancer
13:45 – 14:00 Dr. Fatima Mraiche College of Pharmacy, Qatar University, Qatar
Dr. Mraiche received her BSc. in Pharmacology with distinction at the University of Alberta (Edmonton, Alberta, Canada). After completing her BSc in 2004, Dr. Mraiche pursued a PhD in Medical Sciences at the University of Alberta. She graduated in 2010, receiving numerous national and provincial scholarships, including the Canadian Institute of Health Research Frederick Banting and Charles Best Doctoral Scholarship, Heart and Stroke Foundation Doctoral Scholarship and the Alberta Heritage Foundation for Medical Research Doctoral Scholarship. Currently, Dr. Mraiche is an Associate Professor and the Chair of the Pharmaceutical Sciences Section at the College of Pharmacy, Qatar University.
Dr. Mraiche specializes in cardiovascular research and has extensive training in molecular biology, generation, maintenance and characterization of transgenic animals and adenoviruses, all highly specialized biomedical techniques. She has extended her research portfolio to identifying therapeutic targets for the treatment of lung adenocarcinomas with focus on the mitogen activated protein kinase cascade.
Dr. Mraiche has published seventeen peer-reviewed papers in international peer reviewed journals. She has also presented and published at international and national scientific conferences. Dr. Mraiche has received various competitive grants as principal investigator from the Qatar National Research Fund, including the major National Priorities Research Program (NPRP) fund.
Inhibition of p90 ribosomal s6 kinase potentiates cisplatin
induced apoptosis, cell cycle arrest and anti-metastasis in
human lung adenocarcinoma Nabeel Abdulrahman1, Siveen Kodappully Sivaraman2, Shahab Uddin2 and Fatima Mraiche1* 1College of Pharmacy, Qatar University, Doha, Qatar 2Translational Research Institute, Hamad Medical Corporation, Doha, Qatar
Background: World Health Organization reports that cancer is a leading cause of death worldwide, accounting for 8.8 million deaths in 2015, of which the major portion is due to lung cancer. Cisplatin has been widely used in the treatment of various types of cancers including lung carcinoma. However, drug resistance and cardio toxic side effects by cisplatin
THE 7TH ANNUAL MEETING OF THE MEACR – GAZIANTEP. TURKEY 5
are major concerns which limit their usage. To evade these limitations, cisplatin is co-administered with agents that enhance the sensitivity of cisplatin. Targeting signalling pathways that promote cell survival and proliferation of tumor cell would be highly recommended to inhibit progression of cancer. The mitogen activated protein kinase (MAPK) pathway including extracellular signal regulated kinase (ERK) and its downstream mediator, p90 ribosomal s6 kinase (RSK), is responsible for the regulation of various cellular events.
Methods: Our study examined the effect of BI-D1870 (RSK inhibitor) on cisplatin induced anti-metastasis, apoptosis and cell cycle arrest in A549 human lung adenocarcinoma cells. Cells were treated with cisplatin (32 μM) in the presence and absence of BI-D1870 (7.5 μM). To assess the anti-metastatic activity, cell migration assay was performed, where the ability of cells to migrate through a scratch wound drawn through a confluent cell culture plate was analyzed by measuring the scratch width. Western blotting was carried out to analyse the effect of treatment on the expression of various cell survival proteins (ERK and RSK), and those proteins involved in apoptosis (caspase 9, caspase 3, PARP). Flow cytometric cell cycle analysis was carried out by propidium iodide staining.
Results: The cell migration assay showed that the co-treatment of BI-D1870 with cisplatin inhibited the migration of cells across the scratch width when compared to cisplatin alone (74.2 ± 8.7 % cisplatin vs 16.6 ± 4.3 % cisplatin + BI-D1870, P = 0.0030). This suggested that BI-D1870 potentiated the anti-metastatic action of cisplatin. The combination treatment also resulted in increased expression of cleaved caspase 3, compared to cisplatin (84.6 ± 6.7 % cisplatin vs 142 ± 10 % cisplatin + BI-D1870, P = 0.0123). This indicated that BI-D1870 increases the apoptosis of cancer cells by increasing the sensitivity of cisplatin. The combination treatment also showed a non-significant increase in the cell number in S-phase when compared to cisplatin alone, suggesting a cell cycle arrest at S-phase.
Conclusion: Our results demonstrated that co-treatment of BI-D1870 along with cisplatin potentiated the anticancer activity of cisplatin in A549 lung cancer cells mainly through apoptosis and antimetastasis as shown by the increased cleaved caspase 3 expression and enhanced inhibition of cell migration respectively. These findings implicates that agents targeting RSK mediated cell survival pathway, has an applicability to be used as a combination drug along with cisplatin, as an adjuvant to chemotherapy against lung cancer.
14:00 – 14:15 Dr. Muhammad SAFDAR Department of biology, Virtual University of Pakistan, Pakistan
Dr. Muhammad SAFDAR is an Instructor (Biology) in the Department of Biology, Virtual University of Pakistan where he has been a faculty member and a student of doctorate since 2016.
Moreover, Muhammad is completed his M. Phil (Genetics and Bioengineering) at UVAS, Turkey. His Doctor of Veterinary Medicine (DVM) degree has been done in 2011 at UVAS, LAHORE, Pakistan. His research interests lie in the area of cancer genetics, polymorphisms, drug discovery, nanoparticles, especially cloning, transduction and protein estimation. He has collaborated actively with researchers in several other disciplines of medical and molecular biology, zoology, biostatistics, biotechnology, chemistry, particularly nanobiotechnology and use of nanoparticles in the treatment of breast cancer.
THE 7TH ANNUAL MEETING OF THE MEACR – GAZIANTEP. TURKEY 6
He has total more than 50 publications, more than 200 citations and about 65 impact factors. He is being supervision of undergraduate and post-graduate students. He is working on three different projects currently with a scientific team at Virtual University of Pakistan.
Novel Relationship between 3'UTR region of EGFRs and miR-
4533 genes with SNPs in Colorectal Cancer: In Silico and in
Vivo Muhammad Safdar*1, Yasmeen Junejo1, 2, Sana Zaheer1, H. Khawar Ali1, Sadaf Pervez1, M. Asad Akhtar3, Saima Mustafa1, M. Tariq Pervez2, Tanveer Hussain1, M.E.Baber1
1. Department of Biotechnology, Faculty of Science and Technology, Virtual University of Pakistan. 2. Department of Bioinformatics and Computational Biology, Virtual University of Pakistan. 3. Department of Medical Biology, Faculty of Health Sciences, University of Tromsø, Norway.
Animal Reproductive Biotechnology Institute, Guangxi University, China *Presenter email: [email protected]
Background: Epidermal growth factor receptors or EGFRs along with signaling pathways activated by these receptors have been found to involve in the development of colorectal cancers including its resistance to treatment with cytotoxic medicines. Anti-EGFRs, unresponsiveness to endocrine and poor prognosis has been found to be associated with colorectal cancer. EGFR is found to be involved in colorectal cancer and hence various clinical experiments are trying to test the role of anti-EGFR directed therapy. However, the rate of mutations in EGFRs is not well-defined.
Objective(s): The objective of this study was to specify miRSNPs on EGFRs and SNPs in miR-4533 genes targeting 3'UTR, and evaluate the effect of these with respect to apoptosis and cancer in colorectal by using computational analytical tools and qRT-PCR.
Methodology: We have done analysis using various computational tools such as microT-CDS, miRTarBase, miRcode etc. and we have got sequences from NCBI website and also with qRT-PCR.
Results and discussion: We detected 150 different miRNA binding sites (115 different miRNAs) and 51 different SNPs in binding sites of miRNA in 3'UTR of EGFRs gene. During this study we found that miR-4533’s binding site on EGFR has the SNP on EGFR 3'UTR and its genomic sequence has three SNPs association with the rs567034162 due to same binding site. Also, miR-6509-5p has two SNPs association with the rs920952718 due to same binding site. Here, miRSNP at EGFR 3'UTR and SNP miR-4533 genomic sequence cross-matches at the same site of binding region showed more effective results through qRT-PCR.
Interestingly, miR-4533’s binding site on EGFR has the SNP on EGFR 3'UTR and its genomic sequence has two SNPs association with the rs567034162 due to same binding site. Also, miR-6509-5p has three SNPs associated with the rs920952718 due to same binding site. Here, miRSNP at EGFR 3'UTR and SNP miR-4533 genomic sequence cross-matches at the same site of binding region displayed very effective outcomes via qRT-PCR. Besides, miR-4533 targets many cancer/apoptosis related genes such as RGPD8, COX15, SERPINA3, IL12RB2, OSTF1, MYOM2, PIAS2, HJURP, HOXA6, TCTN1, although it had no cancer/apoptosis related interaction proven before.
Conclusions: This means that miR-4533 may also have a critical effect on apoptosis via different pathways other than EGFRs. Hence, we may deduce that this is the first study
THE 7TH ANNUAL MEETING OF THE MEACR – GAZIANTEP. TURKEY 7
demonstrating an association between miR-4533 and cancer/apoptosis upon computational analysis in silico and in vivo. However, further studies are recommended to have better insight.
Keywords: EGFRs, 3′UTR region, miR-4533, SNPs, Computational analysis, qRT-PCR, HCT-116 cancer cells.
14:15 – 14:30 Dr. Ajaz Bhat
Sidra Medical & Research Center, Qatar
Dr. Bhat is currently working as a research scientist at Dept. of Translational Medicine, Sidra Medical and Research Center, Doha, Qatar. He completed his Ph.D. from one of the premier institutes (All India Institute of Medical Sciences, AIIMS) in India. After his Ph.D., he moved to Vanderbilt University Medical School, Nashville, TN, USA for postdoctoral fellowship. During his eight years of postdoctoral training at Vanderbilt, he has gained wide experience in the field of cancer biology. His focus of research was on the role and regulation of tight junction proteins (Claudins) in colorectal cancer and the role of bile acid induced APE1/Ref1 in esophageal adenocarcinoma. He has published in well reputed journals like GUT, Oncogene, Cancer Research, Molecular Cancer and many more enlisted in his CV. He has attended many international meetings, conferences, symposia to present his research results. He has been also awarded from Immunology society and American Association of Cancer research. He is an active member of many immunological and cancer societies. He is also serving in the review committee of many journals.
Curcumin regulates proliferation, autophagy, apoptosis and
modulates intestinal barrier function in human colorectal
cancer cells Ajaz Bhat1, Jayaprakash Babu2, Roopesh Krishnakutty3, Sheema Hashem1, Santosh K. Yadav1, Shahab Uddin3, Punita Dhawan2, Mohammad Haris1 1 Division of Translational medicine, Sidra Medical and Research Center, Qatar, 2University of Nebraska medical center, Omaha, NE-68198, 3 Translational Research Institute, Hamad Medical Corporation, Qatar
Background: Colorectal cancer (CRC) is the third most common cancer in Qatar and a major health concern for the Qatari population. According to the National Cancer Strategy Qatar, rates of CRC incidences are expected to increase despite significant advances are made in the screening/diagnosis of the disease. Furthermore, it is the tumor progression especially metastasis to distant organs that causes the CRC-patients to die. Thus, dire need for alternative therapies with the potential to inhibit key signaling pathways that regulate CRC-progression/metastasis is crucial. Epidemiological data suggest that dietary manipulations play an important role in the prevention of many human cancers. Curcumin, the yellow pigment in turmeric has been widely used for centuries in the Asian countries without any toxic effects. Curcumin is a naturally occurring powerful anti-inflammatory medicine. The anticancer properties of curcumin have been shown in cultured cells and animal studies. Curcumin has promising potential in cancer prevention and therapy by interacting with proteins and modifying their expression and activity, which includes transcription factors, inflammatory cytokines, and factors of cell survival, proliferation, and angiogenesis. In this
THE 7TH ANNUAL MEETING OF THE MEACR – GAZIANTEP. TURKEY 8
study, we investigated the effect of curcumin on proliferation, autophagy, apoptosis and tight junction proteins.
Methodology: SW480, HT29 and HCT116 cells were exposed to curcumin (0, 10, 20 and 50uM) for 24hrs. The protein expression levels of apoptotic, autophagy markers and tight junction proteins were evaluated by immunoblotting. The CellTiter 96 Aqueous One Solution Cell Proliferation Assay was used for determining the number of viable cells. Colony forming and wound healing assay were used to examine the curcumin effect on tumorigenic and/or invasive abilities of the cell lines. STAT3 transcription activity was studied by luciferase reporter assay. Immunofluorescence assay was used to examine the localization of tight junction proteins after exposure to curcumin.
Results: Exposure of SW480, HT29 and HCT116 cells to curcumin led to decrease in cell proliferation and increased apoptosis in a dose- and time- dependent manner. Assays using growth in soft-agar and wound healing further confirmed ability of curcumin to decrease tumorigenicity. Tight junction proteins (claudin-1 and claudin-7) were found to be altered in expression and localization pattern. Moreover, treatment with curcumin induced autophagy in a dose- and time- dependent manner. Finally, treatment with curcumin increased the expression levels of p-JNK however, treatment with autophagy inhibitor alone or in combination with curcumin prevented the upregulation of p-JNK.
Conclusion: Taken together, outcome from our study suggests that the curcumin treatment of human colorectal cancer cells induces apoptosis and autophagy mediated by JNK pathway. Further studies are underway to delineate the signaling axis by which curcumin mediates alteration in tight junction proteins accompanied by repair in intestinal barrier function.
14:30 – 14:45 Dr. Zehra Bozdağ
Pathology Department, Gaziantep University
I graduated from Erciyes University, faculty of medicine and studied as an resident in the pathology department in Inonu University. I am studying as an Assistant Prof in Gaziantep University, Pathology Department from 2012 till now
.
THE EVALUATİON of SATB2 EXPRESSİON in
PRIMARY EPITHELIAL and METASTATIC
TUMORS oh the OVARY
Esra OZ, Zehra BOZDAG Gaziantep University, Pathology Department, Gaziantep, TURKEY
Ovarian cancer is the second most common gynecologic cancer in women and the seventh most common cause of cancer death in worldwide. Differential diagnosis between primary and metastatic neoplasm can be problematic in some cases.
The special AT-rich sequence-binding protein 2 (SATB2) is a nuclear matrix- associated protein that is important for growth and development. SATB2 was shown to be a sensitive and highly specific marker for colorectal carcinomas (CRCs). Based on this, it recommended a useful immunohistochemical marker for metastatic ovarian tumor of colorectal origin.
THE 7TH ANNUAL MEETING OF THE MEACR – GAZIANTEP. TURKEY 9
SATB2 expression also reported in lung, breast, pancreas, renal, laryngeal, esophageal carcinomas and bone cancers.
In this study we aimed to evaluate SATB2 expression in primary epithelial and metastatic ovarian tumors, and determine its significance between subtypes.
The samples included in this study were obtained from the archives of Pathology Department, at Gaziantep University from 2004 to 2017. The study group consisted of 148 cases of primary epithelial tumor and 29 cases of metastatic ovary tumor.
54.5% of mucinous carcinomas, 51.7% of endometrioid carcinomas, 18.2% of high grade serous carcinomas, 17.9 of borderline mucinous tumors, 6.7% of borderline serous tumors and 51.7% of metastatic ovarian tumors showed SATB2 immunopositivity. SATB2 expression showed no specificity for all the subgroups.
Metastatic ovarian tumors consisted of colon, breast, upper gastrointestinal system and appendix also showed SATB2 expression in different rates. All the colorectal carcinomas showed SATB2 positivity compatible with the literature.
To best of our knowledge, our study is the first study that shows SATB2 expression in primary ovarian tumors in addition to metastatic ovarian carcinomas. We determined SATB2 in all groups of primary and metastatic ovarian tumors. Further studies including larger scales are warranted to show SATB2 specificity for the subtypes.
Keywords: metastatic, ovary tumor, primary, SATB2
Session Chairs: Dr. Shamal Al Muffti & Dr. Fatima Mraiche
15:30 – 15:45 Dr. Wassim Almahli Faculty of Medicine, Gaziantep University, Gaziantep, Turkey
Dr. Wassim ALMAHLI was born in Damascus /Syria in 1977 where he received his secondary education. He graduated from the Faculty of Medicine of Aleppo University in 2001, and got his general surgery specialty from Aleppo university hospital in 2009. His thesis concentrated on the surgical management of hepatic traumas. Dr. Wassim worked in private hospitals in Aleppo until 2010. He began his fellowship in the general surgery department at Gaziantep University hospital / Turkey and increased his practical experiences especially in the field of the cancer surgery. After finishing his fellowship; he became an assistant professor of the general surgery and a member of the academic staff in the English section of the medicine faculty of Gaziantep in 2013. During his academic practice he produced numerous scientific publications and conference presentations.
The Evaluation of Cd117 (C-Kit) Expression in Liposarcomas
Wassim ALMAHLI1, Zehra BOZDAG 2, Ersin BORAZAN1, M. Avni GOKALP1 Omer Faruk DIZIBUYUK2, Metin KARAKOK2 1 Gaziantep University, Department of General Surgery, Gaziantep, Turkey 2 Gaziantep University, Department of Pathology, Gaziantep, Turkey
THE 7TH ANNUAL MEETING OF THE MEACR – GAZIANTEP. TURKEY 10
Introduction: Liposarcoma (LS) is the most common soft tissue sarcomas in adults. They importance of these tumors based on their high risk of local recurrences and distant metastases.CD117(c-Kit) is a type III receptor tyrosine kinase (RTK) that acts as a receptor for mast cell growth factor(also known as stem cell factor or kit ligand) , plays a crucial role in cancer occurrence as an oncogene.
In this study we aimed to investigate the expression of CD117 (c-Kit) in liposarcoma, and to detect the importance of this expression in the differential diagnosis of subtypes for the diagnosis and treatment.
Materials and Methods: The materials included in this study were obtained from the archives of the Department of Pathology, Gaziantep University. The study group consisted of 43 cases of LSs. One representative tissue block from each case was selected and immunohistochemical antibody of CD117 was studied using an automated immunohistochemistry-staining device the cases were considered to be positive when >1% tumor cells showed cytoplasmic CD117 expression with any intensity.
Results: Nine (20.9%) of - (6 myxoid, 2 pleomorphic, 1 well differentiated LS) - 43 LS cases showed CD 117 expression. The expression was focal in all cases.
Discussion: There have been several reports of CD117 expression in limited soft tissue tumors. Hornick and Fletcher performed immunohistochemical analysis for CD117 in 365 soft tissue sarcomas. They found no CD117 expression in LSs. Our study showed focal positivity in different subgroups. Depending on the positive CD117 expression results. Tyrosine kinase inhibitors (TKI) can be placed in the treatment of tumors such as gastrointestinal stromal tumors.
Conclusion: Further studies with large number of cases are warranted to evaluate the CD117 expression in liposarcoma and the effect of possible use of TKIs for the treatment.
Key Words: CD117, C-Kit, Liposarcoma
15:45 – 16:00 Dr. Hiba Bawadi Biomedical Research Center,
Qatar University, Qatar
Dr. Bawadi is a professor in Nutrition and an expert in nutritional epidemiology of non-communicable diseases. Dr. Bawadi published 50+ refereed papers, presented 29 papers in international meetings, and held 17 workshops on clinical nutrition of diabetes and obesity for professional nutritionists.
Dr. Bawadi is currently the Chair of the Continuous Professional Development of Health Practitioners of the health cluster at Qatar University. She is also associated with the Department of Biomedical Sciences of Qatar University.
Preventive and etiological role of nutrition in Oral and
Pharyngeal Cancers Hiba Bawadi and “Mo’ez Al-Islam” Faris
Oral and pharyngeal cancers (OPC) are ranked as the as the sixth most common neoplasms. Dietary factors linked to increased risk of OPC include increased consumption of red meats
THE 7TH ANNUAL MEETING OF THE MEACR – GAZIANTEP. TURKEY 11
and saturated fats. On the other hand, some dietary factors were linked to reduced risk od OPC such as consuming enough fruits and vegetables, legumes, unsaturated fats and dietary intake of bioactive phytochemicals. The molecular mechanisms of action by which dietary factors may influence risk of OPC are not fully elucidated. However, the antioxidation power of dietary antioxidants maintains cell membrane integrity and protects DNA from damage. Other chemopreventive mechanistic actions of dietary factors include the modulation of cell signaling pathways associated with cells proliferation, migration and apoptosis.
16:00 – 16:15 Prof. Hamid Yahya Husain
University of Baghdad, Baghdad, Iraq
WHO, CDC, and Uniceif expert and EMPHNET consultant, poliomyelitis global Eradication, Outbreak response team, global health and immunization. WHO consultant Outbreak alert and response team n Nominated to Emro Regional Counselor of International epidemiological association, Global Health Mentor at Swedish global health mentorship network, Expert consultant Public Health and Epidemiology at Eastern Mediterranean Public Health Network ( EMPHNET)
Professor at Dubai residency training program/ Community and family medicine/ Arab Board for health specializations. Professor of Community Medicine and Public Health Medicine at Faculty of Medicine, University of Baghdad. He also worked as environmental expert ant ministry of environment, Iraq, Worked as training consultant, researcher, and programs manager at ministries of health and higher education and scientific research in different Middle East and North Africa region. Member of editorial Board of Middle east journal of internal medicine, Middle east journal of age and aging, middle east journal of Alzheimer and psychiatry
Dr. Husain is a member of different international, regional and national associations e.g. APHA, IEA, MENAPF, EMAME, American college of occupational and environmental medicine, American college of Epidemiology, American academy of family medicine, Canadian College of family physician,
Supervised more than (30) PhD thesis, 25 MSc thesis, achieved about 150 research work. And contribute to CDC textbook on Ethics in Public Health, cases spanning around the Globe. Editorial Board and Peer Reviewer at many international medical and health Journals
Top 10 cancers Incidence Rates, Pattern and Time Trends of
among Iraqi Population for the last two Decades, Population
and Hospital Based Registry Hamid Yahya Husain1, Sharif F. A. Al-Alawachi2 1Faculty of Medicine, University of Baghdad, Baghdad, Iraq 2Merjan Teaching Hospital Oncology Cancer Center, Babylon Health Directorate, Babylon, Babylonia Email: [email protected]
Background: Global cancer rates have been increasing primarily due to many reasons: an aging population and lifestyle changes in the developing world were major causes. In 2008, approximately 12.7 million cancers were diagnosed, and 7.6 million people died of cancer worldwide.
THE 7TH ANNUAL MEETING OF THE MEACR – GAZIANTEP. TURKEY 12
Objectives: To study the epidemiological patterns of the top 10 registered cancers over the years of 1991-2008 in Iraq. To identify the socio-demographic characteristics and determinants of cancers in Iraq and to identify time trends.
Results: The study revealed that the number of cancer cases registered was 5720 in Iraq (31.05) per 100,000 in 1991 to 14,180 (44.46) per 100,000 population in 2008. While age incidence of cancer in Iraq increased with age, starting from almost 7 cases per 100,000 population at age below 10 years to 398 cases per 100,000 population at age 70 years old, the top 10 cancer incidence in Iraq was breast cancer followed by lung cancer, leukemia, bladder cancer, brain and CNS, non-Hodgkin’s lymphoma, colorectal cancer, stomach cancer, skin cancer excluding melanoma, larynx cancer. Cancer incidence rate significantly increases after 2000 (mean incidence was around 55 cases per 100,000 population) in comparison with the period before 2000 (mean incidence was 40 cases per 100,000 population). The highest age incidence rate is the age of 70 years of (397 per 100,000) followed by 65+ years (327 cases per 100,000 population).
Conclusion: Cancer incidence in Iraq is relatively high and trends are up going in terms of quantity and variables related like age sex etc. The figures reflect little increment due to population growth. Prevention and management of cancer are still inadequate. Recommendations: Strengthening the national cancer prevention, cancer therapeutic and cancer registry program to improve cancer related outcomes; addressing effective interventional strategies in terms of risk management, life style promotion and hazardous exposure through establishing national health related multi-stakeholders projects.
Keywords Incidence Rate; Pattern; Cancer; Iraq
16:15 – 16:30 Prof. Basem Rajab
Istanbul University, Istanbul, Turkey
Dr. Rajab graduated from the University of Sebha-Faculty of Engineering and Technology in 1995. He then worked as a Medical Lab Technician at the University of Tripoli, Faculty of Medical Technology until 2002 afterwards he joined the Abo-Salem Trauma Hospital. Dr. Rajab obtained his MSc. In Biological science from the University of Al-Bayte, Department of Biological science, Al-Mafraq.
Dr. Rajab worked at the University of Tripoli, Faculty of Medical Technology, Medical High institute of Garapoli, Mselata, and then in Abo-Salem, Medical Lab Department until 2012, afterwards he became a staff member at the University of Tripoli, Faculty of Medical Technology, Pathology Department. In 2014 Dr. Rajab joined the University of Kastamonu, Institute of Sciences, Department of Genetics and Bioengineering, Kastamonu, Turkey; where he obtained his PhD. In Immune pathology, Area of research (Evaluating of Homocysteine Variations in Turkish Patients with Correlated Cancer). And in 2017 he joined the Molecular Medicine Department, Aziz Sancar Institute of Experimental Medicine at Istanbul University
THE 7TH ANNUAL MEETING OF THE MEACR – GAZIANTEP. TURKEY 13
A POSSIBLE PROGNOSTIC SIGNIFICANCE OF TIM1 GENE VARIANT
IN LARYNGEAL CANCER Şeyda Ercan1, Dilara Sönmez1,Basem Rajab2,Ayşegül Verim3,Mehmet Tolgahan Hakan1,Bayram Kıran2, İlhan Yaylım1 1Molecular Medicine Department, Aziz Sancar Institute of Experimental Medicine, Istanbul University, Istanbul, Turkey. 2Genetic and Bioengineering Department, Faculty of Science, Kastamonu University, Kastamonu, Turkey. 3Department of Otorhinolaryngology/Head and Neck Surgery, Haydarpasa Numune Education and Research Hospital, Istanbul, Turkey.
Objectives: T-cell immunoglobulin and mucin domain 1 (TIM-1) is a protein that in humans is encoded by the HAVCR1 gene. TIM-1, is a member of the TIM gene family, it is preferentially expressed on Th2 cells and has been identified as a stimulatory molecule for T-cell activation. The relationship between the immune response-related genes and cancer has been demonstrated in a number of studies. This study aimed to investigate possible relationships of TIM-1 gene variant in laryngeal cancer (LC).
Materials-Methods: TIM-1 (416G>C) polymorphism was investigated in 219 subjects (77 subjects with LC and 142 healthy individuals as controls) by using polymerase chain reaction-restriction fragment length polymorphism (PCR-RFLP).
Results: According to our data, it has been found an increased frequency of CC genotype in laryngeal cancer patients but this difference was not statistically significant (p>0,05). The patients who have distance metastasis (%62,5) have increased GC genotypes than those with no distance metastasis (%37,8) and this value was statistically significance (OR:1,652, CI:1,203- 2,267, p= 0,05 ). Moreover; the patients who have node metastasis have increased frequency of G allele (%72,9) than those with absence node metastasis (%54,2) (OR: 1,346, 95% CI: 0,994-1,822).
Conclusion: According to our research, TIM-1 (416G>C) polymorphism is associated with the progression but not on the risk of laryngeal cancer in Turkish population, which is the first data for the contribution of the human TIM-1 gene in laryngeal cancer. Our findings regarding the association of TIM-1 (416G>C) polymorphism and clinicopathological characteristics should be considered in the further studies with larger sample sizes to assess the impact of TIM-1 gene on disease.
Keywords: TIM-1 (416G>C) , polymorphism, laryngeal cancer.
16:30 – 16:45 Mrs. Houda Drissi
University Hassan II of Casablanca, Morocco
DRISSI HOUDA is a PhD student in cancer biology; she carries out her research work at the Mohamed VI center for cancer treatment in Casablanca in collaboration with the faculty of sciences Ben M'sik Hassan II University of Casablanca. She is currently working on a project that focuses on breast cancer, a clinical and biological epidemiological study on hormonal and nutritional risk factors for breast cancer in the Moroccan population.
Today she will present a relevant study entitled: "Breast cancer and hormonal profile about 305 cases collected at the center Mohamed IV for the treatment of cancers in Casablanca."
THE 7TH ANNUAL MEETING OF THE MEACR – GAZIANTEP. TURKEY 14
Breast cancer and hormonal profil about 305 cases collected
at the Mohamed IV center for the treatment of cancers in
Casablanca
DRISSI Houda1. IMAD Fatima Ezzahra1, BENDAHHOU Karima2.. BENIDER Abdelatif 3. RADALLAH Driss1 1: Faculty of Sciences Ben M'Sik Hassan II University of Casablanca Morocco. 2: Cancer registry of the Greater Casablanca Morocco region. 3: Mohammed VI Center for the Treatment of Cancers, Casablanca Morocco.
Breast cancer is the leading woman in terms of incidence and mortality in the world. The objective of our study is the determination of the risk factors, in particular the hormonal factors on the appearance of this pathology.
Our study included 305 newly diagnosed breast cancer patients at the Mohamed IV center for the treatment of Casablanca. Data collection is done using a standardized questionnaire, administered face-to-face to patients and completed from patient records. The statistical analysis of the epidemiological data was done using the R software.
Our study population had a mean age of 50 years with a standard deviation of 11.35; more than half of the patients are married. Most are housewives who live in urban areas.
In our study population parity is on average 3 with a standard deviation of 2.62 and extremes ranging from 0 to 11 children. The average age at first pregnancy of our patients was 23.66 years with a standard deviation of 5.97 and extremes ranging from 11 to 40 years. 96.41% of patients breastfed their children with an average breastfeeding duration of 50.47 months.
56.1% of the patients were menopausal, the average age at puberty was 13.31 years and the average age of onset of menopause was 49.86 years.
The medical history of the study population shows that only 2% of patients had used mammary mastosis treatment, 3.3% of hormone replacement therapy, 6.2% of patients were treated with ovulation inducing agents, 7.2% were treated for irregular cycle and finally 60% of patients used oral contraceptive with an average duration of 8.43 years with a standard deviation of 6.54.
Invasive ductal carcinoma was the most common histologic type in our patients (77.7%) with SBR II grade in 68.3% of patients. Hormonal receptors were overexpressed in 83.26% of cases, 29.9% of patients had HER2 positive and triple negative only accounted for 13.22% of patients.
To deepen our knowledge of the subject of breast cancer, its risk factors and its management in Moroccan women, other etiological studies are recommended to answer these questions.
Keywords: breast cancer, prospective study, hormonal profile.
THE 7TH ANNUAL MEETING OF THE MEACR – GAZIANTEP. TURKEY 15
ORAL PRESENTATIONS: DAY 2 22 December 2017: Gaziantep University, Turkey
Session Chairs: Dr. Abolfazl Movafagh & Dr. Moussa Alkhalaf
9:00 – 9:15 Prof. Zoubida Zaidi University of Setif. Algeria
Dr. Zoubida Zaidi Associate professor on epidemiology from the University of Setif, Algeria and chief of the cancer registry Unit, Setif, Algeria
Trends in cervical cancer survival in Arab
World, 1990-2009 Introduction: Cancer survival is a key measure of the effectiveness of health-care systems. Globally, cervical cancers (CC) represent 530,000 new cases per year and account for the vast majority of all HPV-attributable cancer cases worldwide. Nearly half of the cases are diagnosed in women <50 years old, and more than two-thirds are diagnosed in less developed countries. Cancer is responsible for a substantial proportion of disease burden in the Eastern Mediterranean Region (EMR), Between 2005 and 2015, incident cases increased by 46%, deaths by 33%, Cancer caused 722,000 cases, 379,000 deaths. In females, breast cancer, leukemia, and cervical cancer were the most common incident cancers with 177.4 thousand, 20.8 thousand, and 19.6 thousand cases, respectively
Objective: To describe the trends of the survival of CC patients diagnosed in Arab countries.
Material and Methods: This report is a summary of the two survival figures of CONCORD study 1 (1990-1994) and CONCORD study 2 (1995-2009). Individual cervical cancer tumour records were submitted by 06 population-based cancer registries in Arab countries (Jordan, Saudi Arabia, Qatar, Algeria, Libya and Tunisia) for patients (15-99 years) diagnosed during 1990-2009 and followed up to 31 December 2009. Estimated five-year net survival, adjusted for background mortality by single year of age, sex, calendar year in each country.
Results: Worldwide, data for cervical cancer are available for 602 225 women, 192 registries in 51 countries provided data for 1995–99, 244 registries in 58 countries contributed data for 2000–04, and 244 registries in 61 countries provided data for 2005–09. The global range in 5-year net survival from CC is very wide, particularly in Africa, Central and South America, and Asia. For patients diagnosed during the period 2005-2009, the age-standardized five-years net survivals were respectively higher 70% in Qatar but is based on only 16 cases and the lowest rate between 1995-1999 and 2005-2009 cervical cancer survival was 50% or higher in all other countries, except for Libya (Benghazi, 39%),
Conclusions: Comparison of population-based cancer survival CONCORD study showed very wide variations in survival from cervical cancer in Arab world. Cancer survival research is being used to formulate cancer control and the need to implement effective strategies of primary prevention.
THE 7TH ANNUAL MEETING OF THE MEACR – GAZIANTEP. TURKEY 16
09:15 – 09:30 Dr. Omar Fayez Nimri Cancer Prevention and Control Department, Jordan
Dr Nimri is the head of the cancer prevention and control management, he is also
the director of the Jordan National Cancer Registry. Dr. Nimri obtained his bachelors
degree in 1990 from Pakistan as a surgeon, and went on to obtain several diplomas,
including: Korean Acupuncture from Sri-Lanka in 1991, community medicine from
Jordan in 2002, Cancer Prevention and Control Diploma from the USA in 2006,
Cancer registration and CanReg software from IARC France in 2005/2007 and
Cancer prevention and Etiology Diploma from the UM School of Public Health,
University of Michigan, USA 2008.
Dr. Nimri has many achievements in the field of cancer on local, regional as well as international levels, particularly concerning issues pertaining to cancer burden epidemiology, prevention, screening and registration.
Bladder Cancer, 2005-2010 data. (Four MECC Countries, Jordan,
Turkey, Israel and Cyprus) *** MECC -Middle East Cancer Consortium
Background: Cancer registration is the fundamental backbone of national cancer control plans worldwide, this study compares the cancer data of selected cancer from four of the MECC countries, Bladder cancer in this paper. The analysis involves both the In-situ and invasive bladder cancer.
Much of the variation in bladder cancer incidence internationally may partly be due to different registration practices for low-grade, or non-invasive, of the bladder Ca.
Method: The analysis involves both the In-situ and invasive bladder cancer. Not all risk factors or variables of Bladder Cancer are collected; in the four registries, which restrain full comparison... Age-standardized incidence rates (ASR) calculated with WHO world standard population (2000-2025). Annual percent changes (APC) calculated too.
Result: Males: females Bladder Cancer Ratio in Jordan was 7:1. Age Standard Rates (ASR) were highest among the Israeli-Jewish and lowest rates noted among the Jordanian’s population, Overall ASR (Male, Female per 100,000) Jordanians 7.4 (M:12.8/F:1.9) Israeli-Jewish 17.6(M:31.6/F:6.3).
Age specific incidence rate (ASIR) of bladder cancer increased with the increasing of age especially in males mostly above the age of 70 years, highest Israeli-Jewish (299.17**) Turkish (280.5) Cypriots (274.6) Israeli-Arab (262.4) and Jordanians (89) compared with SEER (351.2).
Data showed that most of the cases were invasive type ranging from (99.3%) among Turkish cases and the lowest was among the cases from Cyprus (77.5%) while the (in-situ) cases highest were among the Cyprus data followed by the Israeli population and the lowest among the Turkish.
Recommendation: Increasing public awareness of bladder cancer and the risk factor may lead or be an attribute to its existence. Prevention should be emphasis with high commitment, avoidance strategies in which person should avoid exposure to any of the risk factors (smoking, certain food, exposure to radiation…) or other agents and try to keep it to the minimum levels.
THE 7TH ANNUAL MEETING OF THE MEACR – GAZIANTEP. TURKEY 17
09:30 – 09:45 Hadeel M. Fayyadh University of Fallujah, Collage of Veterinary Medicine
Fallujah, Iraq
Dr. Fayyadh graduated from the College of Veterinary Medicine- Baghdad University with B.V.M.S. in 2001. Then she completed her M.Sc. study in Medical Microbiology at the College of Medicine- Al-Anbar University in 2007 where she specialized in Medical Microbiology- Virology. Soon after that and since 2008 she worked in College of Veterinary Medicine at Fallujah University as a lecturer at the Department of Microbiology. During that time she obtained her PhD in Medical Microbiology-Virology with a scholarship at the College of Medicine- Al-Mustansiriyah at 2015, then she went back to teaching at the same university. During her carrier, she taught different scientific subjects including Biology science, Immunology, and Virology. Her interests are in the field of viral diseases where she conducted more than 7 scientific projects on this issue, and her findings were published in local and international journals. She also presented her work at various local conferences in Iraq.
Serological and molecular detection of humanherpes virus
type 6 infection in Iraqi patients with acute and chronic
lymphocytic leukemia
Background: Human herpesvirus type 6 (HHV-6) is associated with roseola infantum during childhood followed by life-long latency that periodically reactivated in immuneocompromised individuals causing serious consequences. In spite of several studies to establish the pathogenic role of HHV-6 in lymphoid malignancies, the issue is still controversial.
Objectives: The present study was arranged to explore the association of HHV-6 infection among Iraqi patients with acute and chronic lymphocytic leukemia using different serological and molecular techniques.
Patients and methods: This cross-sectional case control study was conducted in National Center for Hematological Diseases (NCHD) at Al-Mustansyria University and Baghdad Teaching Hospital (BTH) in Baghdad-Iraq from September 2013 till November 2014. A total of 29 patients consists of 24 patients with acute lymphocytic leukemia and 5 patients with chronic lymphocytic leukemia of both sexes, the age range was 14-80 years. The diagnosis of lymphomas was based on hematological and histopathological criteria. 59 apparently healthy individuals from unpaid blood donors were enrolled as control group. The age range was 14-59 years. Human privacy was respected by taken participant's oral consensus. The anti- HHV6 IgG antibody was detected for all patients and control by two different methods using ELISA and IFAT, while the anti- HHV6 IgM antibody was detected by ELISA. Real -Time PCR was done for quantification of the HHV6 A-B genome. Statistical analysis was done using the Statistical Package of Social Science (IBM-SPSS), Version 23, and P values less than 0.05 were considered significant.
Results: The anti-HHV6 IgG was positive in (70.8%) of the patients with ALL and (61.0%) of the controls by IFAT technique. Likewise, the ELISA results showed insignificantly higher positivity rate among patients compared to healthy individuals (87.5% Vs 72.9, p =0.151). on the other hand, all the 5 patients (100%) with the CLL were positive for anti-HHV6 IgG by
THE 7TH ANNUAL MEETING OF THE MEACR – GAZIANTEP. TURKEY 18
IFAT, versus (61.0%) of controls were positive. Again using the ELISA technique, the anti-HHV6 IgG positivity rate among CLL patients was 80%, while that of control group was 72.9%. However, the difference was statistically insignificant (p=0.729). Regarding the PCR results, the HHV-6 DNA was detected in only one patient with ALL (4.2%), while the viral DNA was not detected in any of the controls. Similarly, the viral DNA was not detected by PCR among CLL patients.
Conclusion: Although a higher anti-HHV-6 antibodies positivity rate among patients with ALL and CLL, the pathogenic role of the virus in the development of these malignancies was difficult to be ascertain.
Keywords: Human herpesvirus-6, anti-HHV-6 antibodies, ALL, CLL.
9:45 – 10:00 Ms. Fatima Ezzahra Imad University Hassan II of Casablanca, Morocco
Imad Fatima ezzahra is a PhD student in cancer biology; she carries out her research work at the center Mohamed VI for the treatment of cancer in Casablanca in collaboration with the faculty of sciences Ben M'sik Hassan II University of Casablanca. She is involved in a project on colorectal cancer, a clinical and biological epidemiological study and nutritional risk factors for colorectal cancer in a Moroccan population.
Today she will present us a relevant study entitled: "Colorectal cancer in patients younger than 40 years: experience of the Mohamed IV center for the treatment of cancer."
COLORECTAL CANCER IN PATIENTS YOUNGER THAN 40 YEARS:
EXPERIENCE OF THE MOHAMED IV CENTER FOR THE TREATMENT OF
CANCER 18Fatima Ezzahra IMAD, 1Houda DRISSI, 2Sofia Majdoul, 2Nezha TAWFIQ, 3Karima BENDAHHOU, 4Nadia TAHIRI JOUTI, 2Abdellatif Benider, 1Driss RADALLAH. 1: Faculté des Sciences Ben M'Scik Université Hassan II de Casablanca, Maroc. 2 : Centre Mohamed VI pour le traitement des cancers, CHU Ibn Rochd , Faculté de médecine et de pharmacie, Université Hassan II, Casablanca, Maroc. 3 : Registre des cancers de la région du grand Casablanca, Maroc. 4 : Faculté de médecine et de pharmacie, Université Hassan II, Casablanca, Maroc
Colorectal cancer is the most common form of digestive cancer in the world. This location is rare in patients under 40 years old. Actually, it’s known to have a poor prognosis. The objective of this work is to study the epidemiological, clinical, pathological and therapeutic profile of this cancer in young people compared to the elderly taken in charge at the Mohammed VI Center for cancers treatment during the years 2014-2015.
This is a cross-sectional study, including cases of colorectal cancer in the Center. Data collection was based on patient records and analyzed by R software.
During the study period, 330 patients were included and divided into two groups: G1 <40 years and G2> 40 years.
THE 7TH ANNUAL MEETING OF THE MEACR – GAZIANTEP. TURKEY 19
15% of patients were less than 40 years old. There is a slight male predominance, with a sex ratio of 1.04. The presence of a history of CRC in first-degree relatives was noted in 11 patients in the G1 group (22.45%), and in the G2 group (8.89%), p = 0.03.
The rectum tumor was found in 40.8% for the G1 vs 51.6% for the G2. In addition, sigmoid colon cancer was the most frequent tumor site of colonic cancers in both groups.
The adenocarcinoma Lieberkühn accounted for 83% of all tumors in the elderly vs. 69.39% in the young (p = 0.01). Mucinous carcinomas were more frequent in young patients (24,49% vs. 13,16 %; p=0,01).
In our study, protocols of cancer treatment colic were in 83 % of elderly people and 50 % young people by the association surgery and chemotherapy. Exclusive surgery was practiced in 16 % young people and 4 % of eldery (p=0,001), and the palliative chemotherapy in 33 % young people vs 16 % of eldery.
For the rectal cancers, treatment was principally a preoperative radiotherapy associated to the surgical treatment in 66 % young people and 75 % of eldery, Additional the adjuvante chemotherapy in 73,3 % of eldery and 39 % young (P=0,007)
10:00 – 10:15 Prof. Feras Alali College of Pharmacy, Qatar University, Qatar
Prof. Feras Alali, Bsc Pharmacy, Jordan University of Science and Technology
(JUST), PhD in Medicinal Chemistry and Molecular Pharmacology, Chemistry of
Natural Products, Purdue University. Since Sept. 2013, Prof. Alali is the Associate
Dean of Research and Graduate Studies, College of Pharmacy, Qatar University. Dr
Alali is world authority in nature-based drug discovery and development. His
research interest spans from novel new anticancer agents to treating stress
associated cognitive impairment. To his credit are 78 international, peer-reviewed
publications, two book chapters and a USA patent. Dr Alai served two term Dean of
Pharmacy and Founder Director of Research Center. Dr Alali was awarded the
Highest National Recognition Award in Science - Pharmacy in Jordan in 2008 (Royal
Decree). Currently, October, 2017, Dr Alali’s Elsevier Scopus h index is 20 with 1765
total citations, ResearchGate h index 22 with 2088 total citations, and Google
Scholar h index of 25 and i10-Index of 46 with 2667 total citations.
7-O-Methylpunctatin: A Homoisoflavonoid Scaffold with
Antimetastatic Potential against MDA-MB-231 Breast Cancer
Cells Alaaeldin I. Saleh1, Tamam El-Elimat2, Ali Eid3,*, and Feras Q. Alali4,2* 1. College of Medicine, Qatar University, Doha 2713, Qatar. 2. Department of Medicinal Chemistry and Pharmacognosy, Faculty of Pharmacy, Jordan University of Science
and Technology, Irbid 22110, Jordan 3. Department of Pharmacology and Toxicology, Faculty of Medicine, American University of Beirut, Beirut
1107-2020, Lebanon 4. Faculty of Pharmacy, Qatar University, Doha 2713, Qatar
THE 7TH ANNUAL MEETING OF THE MEACR – GAZIANTEP. TURKEY 20
7-O-Methylpunctatin, a recently in-house discovered homoisoflavonoid from the bulbs of Bellevalia eigii Feinbrun (Asparagaceae), was studied for their effects on the proliferation, migration, invasion, metastasis, and tumor growth of triple negative MDA-MB-231 breast
cancer cells. 7-O-methylpunctatin at 20 M was found to inhibit proliferation, migration, and adhesion of breast cancer cells and to attenuate invasion. 7-O-methylpunctatin inhibitory action against migration and invasion could be attributed to induction of cell aggregation, upregulation of occludin, and downregulation of uPA. However, cell adhesion was inhibited via NF-kB downregulation. Additionally, cellular senescence, autophagy, cell cycle arrest, and reactive oxygen species were induced by 7-O-methylpunctatin treatment indicating that 7-O-methylpunctatin exerts its anti-proliferative activity by G0/G1 cell cycle arrest, and caspase pathway activation. MAPK, PI3K/Akt pathways were suppressed upon treating MDA-MB-231 cells, indicating their role in 7-O-methylpunctatin inhibition of migration and invasion. The results obtained in the current study identified 7-O-methylpunctatin as a potential novel therapeutic treatment of breast cancer metastasis that warrants further studies and development.
Session Chairs: Dr.Zehra Bozdak & Dr. Hamid Yahya Husain
10:45 – 11:00 Prof. Moussa Alkhalaf College of Medicine, Qatar University, Qatar
Professor Moussa Alkhalaf was born in Aleppo, Syria, in 1960. He obtained his BSc Biology in 1981. He obtained PhD in Biomedical sciences from the University of Franche Comte in Besancon (France). In 1990, he joined the Department of Cellular and Molecular Biology at the University of Manitoba (Canada) to work on variant estrogen receptors and their role resistance in breast cancer. In 1993, he worked a researcher at the Institute of Genetics and Cellular and Molecular Biology at Luis Pasteur University in Strasbourg University and he developed a transgenic model with mdm2 oncogene. In1998, he joined Kuwait University and he obtained the 2006/2007 Kuwait University Distinguished Researcher Award. His book “the Genomic Era” was awarded the 2006 Best Published Book Prize in the Arab World by Jerash University (Jordan). Currently, he is full professor and serves as the Director of PhD Medical Biochemistry Graduate Program in Department of Biochemistry.
How valuable is BRCA1 evaluation? Mutations pattern in
Kuwaiti breast cancer patients
For decades after the discovery of BRCA1 as one of the genes responsible for the development of breast cancer in women, several questions about its role still unanswered. Data from literatures showed that BRCA1 mutation carriers have a lifetime risk of developing breast cancer in some human populations. However, the role of BRCA1 in other populations including Arab women has not yet been explored. Our study was to analyze the role of BRCA1 mutations in breast cancer women from Kuwait.
DHLPC followed by DNA sequencing were used to analyze BRCA1 sequence variations for 116 unselected breast cancer patients (mean age: 49.15 years, range from 27-76 years) and 119 matching healthy controls (mean age: 47.89 years, range 31-70 years). Around 69% of the
THE 7TH ANNUAL MEETING OF THE MEACR – GAZIANTEP. TURKEY 21
patients have at least one change in their BRCA1 sequence. There was no significant difference in the age of onset between patients having changes in the sequence and patient without sequence changes (48.72 years for patients with sequence changes, 50.18 years for patient with the wild type sequence). Surprisingly, 61% of the healthy controls showed BRCA1 sequence variation as compared to the published BRCA1 sequence. In total, 30 BRCA1 sequence variants were identified in the Kuwaiti breast cancer population. 25 sequence variants were detected at the heterozygote level and five variants were present at the heterozygote and homozygote levels. Most of these variants were also present in healthy controls.
We show here that the spectrum of BRCA1 mutations in Kuwait is different from all studied populations. We observed that Kuwaiti women with certain variants have increased risk for developing breast cancer (p<0.05) and these variants were not known as full mutations. The discrepancy in BRCA1 mutations will be discussed.
11:00 – 11:15 Prof. Mohamed Nizar Akil Faculty of Medicine, Gaziantep University, Turkey
Medical Degree- Faculty of Medicine- University of Aleppo- Syria 1973
C.E.S Degree in Pathology (Histopathology) Pierre & Marie Curie University – Paris - France 1981 Professor of Pathology – University of Aleppo - Syria 1982-2012 Professor of Pathology – Gaziantep University- Turkey 2012 – 2017 Member of International Academy of Pathology (IAP)-Arab division Main interests; GIT, breast, bone and soft tissue pathology. Email; [email protected]
The role and clinical impact of genetic in breast cancer
Breast cancer is the most common malignancy accounting for 29% of all female cancers and responsible for 15% of cancer deaths in women.
Breast cancer is a multifactorial disease, which may involve an interaction between environmental, lifestyle, hormonal and genetic factors. Genetics is estimated to be responsible for 5 to 10 out of 100 cases of breast cancer, but 75% of women with this cancer have no readily identifiable risk factors.
About 5% of all breast cancers are largely attributable to inherited mutations in specific genes including BRCA1, BRCA2 and TP53.
Hereditary breast cancer is usually characterized by early age of onset, a high incidence of bilateral disease and with a family history of other malignancies, nevertheless some cases of “sporadic” breast cancer occur in women who carry a high-penetrance breast cancer susceptibility gene mutation but do not have a family history of breast cancer; other genes, such as PALB2, TP53, PTEN, CDH1, and STK11, confer a risk to either or both of these cancers with relatively high penetrance.
Additional genes, such as CHEK2, BRIP1, RAD51, and ATM, are associated with breast and/or gynecologic cancers with moderate penetrance.
THE 7TH ANNUAL MEETING OF THE MEACR – GAZIANTEP. TURKEY 22
Although such cancer susceptibility genes are very important, highly penetrant germline mutations are estimated to account for only 5% to 10% of breast cancers overall.
11:15 – 11:30 Dr. Elif İşbilen Department of Biochemistry, Gaziantep University, Turkey
Dr. İşbilen received her undergrad education from İstanbul Medicine Faculty in 2003, She then obtained her postgraduate degree from Gaziantep University, Department of Biochemistry in Turkey. She is Currently working as a medical professional and assistant professor at Department of Biochemistry of Gaziantep University. Before that she worked for two years at Ankara University and Ibni-Sina Hospital Biochemistry Department, She also worked for 5 years at Baskent University, Konya Application and Research Hospital
Prognostic Roles of B-Cell Lymphoma 2
(Bcl-2) Expression in Breast Cancer
Hülya Çiçek¹, Mustafa Yıldırım², Özlem Saygılı¹,Elif İşbilen¹, Hasan Ulusal¹ ¹Gaziantep University, Department of Biochemistry ²Bahçeşehir University, Department of Internal Medicine
When breast cancer is diagnosed early, it is very important that the sensitivity of the diagnostic tests is high so that adequate treatment is available, progress can be stopped and complications can be prevented.
In this concept, the relationship between Bcl-2 protein, which plays a vital role in the carcinogenesis process, as a predictor of breast cancer, the sensitivity of Bcl-2 protein, and breast cancer was examined in this study.
Current studies suggest that Bcl-2 is a reliable prognostic marker, especially for hormone receptor (HR) positive breast cancer. Bcl-2 positive breast cancer patients have a better prognosis than overall survival and relapse-free survival. In addition, Bcl-2 exhibits different prognostic features depending on the molecular subtype of breast cancer.
Bcl-2 expression has been shown to be a positive prognostic factor for 5-year relapse-free survival and disease-specific survival in luminal breast cancer.
The patients with histopathologically diagnosed breast invasive ductal carcinoma between 2014 and 2017 in Medicalpark Gaziantep Hospital, were diagnosed and healthy volunteers were included in the study.
The samples obtained from patients and healthy volunteers were studied by ELISA method in Biotek-ELx808 device.
It is found that there is a significant correlation between Bcl-2 levels in the patient-control group (p <0.001). Bcl-2 levels are 478.1 ± 353.6 U / mL (Range 196.7-2554.7) in the patient group and 286.4 ± 106.1 U / mL (Range 31.9-521.6) in the control group.
When the results of this study are evaluated by ROC analysis, it is suggested that Bcl-2 may be used as a marker with a sensitivity of 93% by accepting Bcl-2 as a border value 230 in breast cancer patients.
Keywords: Breast cancer, Bcl-2 protein, apoptosis
THE 7TH ANNUAL MEETING OF THE MEACR – GAZIANTEP. TURKEY 23
11:30 – 11:45 Mr. Ali Pamuk Department of Medical Biochemistry, Gaziantep University
Gaziantep, Turkey
Mr. Pamuk was born in Adana in 1981. After completing his primary and secondary
education in Adana, he moved to Trabzon in order to study at the Chemistry
Department of Karadeniz Technical University in 1999. After graduating from the
University in 2004, he became a high school chemistry teacher, In March 2006, he
went to the United States of America for language training. After staying in the US
for about eight years, he returned to Turkey in August 2013. Ali Pamuk, currently
resides in Gaziantep, is married and has two children.
EXPRESSION AND PURIFICATION OF RECOMBINANT ACTIVE TET
ENZYME IN E.COLI Ali PAMUK, Hülya ÇİÇEK, Khandakar A. S. M. SAADAT
Increasing research on epigenetics in recent years and the inability to explain some of the subjects with genetically, have necessitated the uncovering of epigenetic mechanisms. As a result of the epigenetic studies made, it has been found that the deterioration of the epigenetic mechanisms is associated with many neurodegenerative diseases and especially cancer. DNA methylation is one of the most common epigenetic mechanisms. In recent years, studies have revealed the existence of a protein family called TET, which is responsible for DNA demethylation. These proteins have been shown to actively reverse DNA methylation and to significantly affect the epigenetic control mechanism through the methylcytosine derivatives they form. However, the mechanism of the TET proteins on the highly complex epigenetic changes is still unclear. The kinetic behavior of proteins is thought to be one of these mechanisms of action. One of the most important thing needed at this point is the production of active TET proteins in a large amount in order to study kinetic and mechanistic of TET proteins. In this study, it was aimed to purify the catalytic domain of TET1 protein recombinantly and actively in E. coli bacteria.
Key Words: TET protein, Epigenetics, DNA methylation, DNA demethylation, 5-methylcytosine, 5-hydroxymethylcytosine, Alpha-ketoglutarate enzymes, Non-heme iron enzymes, E. coli, Expression of recombinant protein, Protein purification, SUMO fusion protein.
11:45 – 12:00 Mr. Anas Azzam Ashour College of Medicine, Qatar University, Qatar
Anas Azzam Ashour was enrolled in the College of Medicine of Qatar University in
2015. While he was studying medicine, Anas found interest in research and
especially in the field of cancer. Anas is working on several projects related to the
outcome of water-pipe smoking and human health where he, together with his
colleagues, recently published a paper regarding the effect of WPS during
embryogenesis; meanwhile, they are exploring the outcome of WPS in human
cancer.
THE 7TH ANNUAL MEETING OF THE MEACR – GAZIANTEP. TURKEY 24
Water-Pipe Smoking and Women’s Health: from pregnancy to
breast cancer Anas A. Ashour1*, Mahmoud Y. Haik1*, Khaled W. Sadek1* & Ala-Eddin Al Moustafa1,2 1College of Medicine & 2Biomedical Research Centre, Qatar University, Doha, Qatar Correspondence should be addressed to Ala-Eddin Al Moustafa E-mail: [email protected]; [email protected]
Water-Pipe Smoking (WPS) is the most widespread tobacco use in the Middle-East, and is rapidly spreading globally. This popularity can be attributed to the belief that the WPS is filtered and less harmful than cigarettes, however, previous studies have proven this belief to be inaccurate. Thus, in our lab, we aimed to explore the outcomes of WPS on women’s health focusing on two important aspects which are embryogenesis and breast cancer development. We assessed the effect of WPS during embryogenesis using chicken embryos as a model; on the other hand, two non-invasive breast cancer cell lines were used to explore the role of WPS in breast cancer progression. Our data revealed that WPS can have lethal effects at the early stage of the embryo which was manifested by decelerating the process of angiogenesis as well as deregulating key controller genes of cell proliferation and apoptosis in addition to cell motility. Regarding the outcome of WPS on breast cancer cells, we noted that WPS provokes cell invasion of MCF7 and BT20 cell lines; this is accompanied by a down–regulation of E-cadherin which is considered as a tumor invasion suppressor. Finally, we found that WPS can activate Erk1/Erk2 which could be the main mechanism behind gene deregulations observed during embryogenesis and cell invasion of breast cancer cells. Thus, our data suggest that WPS can have dramatic effect on women’s health from pregnancy to breast cancer development. However, we believe that more studies are necessary to elucidate various aspects of the dramatic effect of WPS on women’s health.
Session Chairs: Dr. Ahmad Ibrahim & Dr. Waleed Arafat
13:30 – 13:45 Dr. Elzem Şen Faculty of Medicine, Gaziantep University, Gaziantep,
Turkey
Dr Elzem Şen is an Assistant Professor in Anesthesiology and Reanimation Department of the School of Medicine, in Gaziantep University, Gaziantep, Turkey. Her research interests reside in the field of cardiovascular anesthesia, transplantation anesthesia and general surgery anesthesia. She visited Universitair Ziekenhuis Gent in Belgium as an observer for three months in 2015. She has 8 international published articles and three national published articles. She has teaching experience of medical student in the area of cardiopulmonary resuscitation.
THE 7TH ANNUAL MEETING OF THE MEACR – GAZIANTEP. TURKEY 25
FOUR-YEAR EXPERIENCE OF PANCREATICODUODENECTOMY AT
GAZIANTEP UNIVERSITY MEDICAL FACULTY HOSPITAL Elzem Sen1, Sitki Goksu1, Ahmet A. Balık2, Ersin Borazan2, Burak Yakar1, Bedri Turhan1 Gaziantep University, Faculty of Medicine, Anesthesiology and Reanimation Department Gaziantep University, Faculty of Medicine, General Surgery Department
Aim: We aimed to present our four-year experience in pancreaticoduodenectomy operations performed in our hospital's operating room.
Material and Methods: A total of 71 patients’ files were evaluated between September 2013 and September 2017, retrospectively.
Results: Twenty-six patients (36.6%) were female and 45 (63.3%) were male, mean age was
61.612.7 years. The mean duration of operation was calculated as 4.21.98 hours. ASA I: 1 (1.4%), ASA II: 39 (54.9%) and ASA III: 31 (43.6%). Pathologically; Adeno Ca 71.8%, Neuroendocrine Ca 7%, Tubulovillous Adenoma 4.2%, Dysplasia 2.8%, Muscular cystic tumor 1.4%, Non-Hodgkin lymphoma 1.4%, Nesidoblastoma 1.4%, Transparent Ca 1.4%, Myoepithelial hematoma 1.4%, serous cystadenoma 1%, Adenosquamous Ca 1.4%, active chronic inflammation 1.4%, adenoma 1.4%, chronic pancreatitis reported as 1.4%. According to Clavien-Dindo classification, low grade (Grade 1-2) complications were seen in 32 (45%) and high-grade complications were in 5 (7%) patients as postoperative complications. Mean follow - up period was 9.12 ± 12.6 months.
Conclusion: Pancreaticoduodenectomy causes serious morbidity and mortality. This surgery which is mostly performed to treat cancer can be performed safely and the results can be accepted with careful patient selection, careful preoperative evaluation, appropriate surgical technique, critical anesthetic care and postoperative intensive care.
13:45 – 14:00 Dr. Gülçin Elboğa Faculty of Medicine, Gaziantep University, Gaziantep,
Turkey
In 2009, Dr. Elboga graduated from Gaziantep University Faculty of Medicine. Between 2010 and 2013, she completed her specialist education at Gaziantep University Medical Faculty Department of Mental Health and Diseases. Between 2011 and 2015 she studied Cognitive and Cognitive Psychotherapy at the Turkish Association of Cognitive and Behavioral Therapies (TACBT). In 2015, he was certified as a Cognitive and Cognitive Therapist by the European Association for Behavioral and Cognitive Therapies, an international academy that assesses this field competence.
Gaziantep between 2015 and 2017. Ersin Arslan Training and Research Hospital completed the mandatory service. At the same time Dr. Elboga tought at Hasan Kalyoncu University Department of Psychology from 2016-2017. In 2017, she was appointed as a teaching assistant to Gaziantep University Medical Faculty Mental Health and Diseases Department. She is currently the President of Gaziantep University Psychiatry Department.
THE 7TH ANNUAL MEETING OF THE MEACR – GAZIANTEP. TURKEY 26
Anxiety, Depression in Carcinoma of Unknown Primary
Patients Undergoing F-18 FDG PET-CT Imaging Procedure Gulcin Elboga*, Elif Karayağmurlu*, Ertan Şahin** * Department of Psychiatry , Gaziantep University ** Department of Nuclear Medicine, Gaziantep University
Background: Many cancer patients accompanied by a high psychiatric morbidity. The distress levels may depend on the type and stage of cancer. Its severity often peak at the initial diagnosis, recurrence, development of treatment-related side effects and with the diagnostic procedures. The aim of this study was to investigate two major mental health disorders, anxiety and depression in carcinoma of unknown primary patients undergoing positron emission tomography-computed tomography (PET-CT).
Methods: Sixty three carcinoma of unknown primary patients (24 male, 39 female) were included in this study. All patients were referred to Nuclear Medicine Department for Fluorine-18 fluorodeoxyglucose (F-18 FDG) PET-CT imaging for the assessment of their malignant or possibly malignant diseases. The Hospital Anxiety Depression Scale and the State and Trait Anxiety Inventory were used to evaluate the anxiety and depression levels in these patients. Descriptive statistics and inferential statistics was performed. SPSS 17.0 was used for analysis. Statistical significance was set at p=0.05.
Results: The mean anxiety and depression scores of The Hospital Anxiety Depression Scale prior to F-18 FDG PET-CT were 8.9 ( ± 3.6) and 6.8 ( ± 3.3), respectively. The mean state and trait anxiety scores of the State and Trait Anxiety Inventory prior to F-18 FDG PET-CT were 40.2 (± 8.3) and 46.5 (± 7.4), respectively. The Hospital Anxiety Depression Scale and the State and Trait Anxiety Inventory anxiety scores were found to be significantly higher in female patients, smokers and in patients hospitalized.
Conclusion: Patients suffering from carcinoma of unknown primary exhibit high levels of anxiety and depression. F-18 FDG PET-CT imaging procedure may at least contribute to patient’s anxiety. Thus, nuclear medicine physicians should examine patients with extreme care in order to reduce this effect most. Sometimes the physicians may not able to prevent some of the effects of cancer. But they have a vital role in recognizing and treating effectively symptoms of anxiety or depression. In this manner, the cost of cancer for human life can be reduced.
Keywords: Anxiety; Depression; carcinoma of unknown primary; PET-CT
14:00 – 14:15 Dr. Neslihan Bayramoğlu Tepe Faculty of Medicine, Gaziantep University, Gaziantep,
Turkey
Dr Neslihan Bayramoğlu Tepe is an Assistant Professor in Obstetrics and Gynecology Department of the School of Medicine, in Gaziantep University, Gaziantep, Turkey. Her research interests reside in the field of general gynecology, perinatology and urogynecology. She visited Hacettepe University Department of Perinatology as an observer for three months in 2016. She has 9 international published articles and 4 national published articles. She has teaching experience of medical student in the area of obstetrics and gynecology.
THE 7TH ANNUAL MEETING OF THE MEACR – GAZIANTEP. TURKEY 27
DETERMİNATİON THE EXPRESSION LEVELS OF miRNA 204-5P,
miRNA 138-5P AND miRNA 133-3P IN FORMALINE FIXED
PARAFFINE EMBEDDED TISSUE SAMPLES OF ENDOMETRIAL
CANCER AND RELATIONSHIP WITH THE PROGNOSIS
Hüseyin Kurt1, Neslihan Bayramoğlu Tepe1, Özcan Balat1, Zehra Bozdağ2 1) Gaziantep University School of Medicine Department of Obstetrics and Gynecology 2) Gaziantep University School of Medicine Department of Pathology
Aim: In our study, we aimed to elucidate the function of micro RNAs which have been considered as prognostic biomarkers guiding for early diagnosis and individualized therapy of endometrial cancer (EC). In this context, we determined the expression levels of miRNA 204-5p, miRNA 138-5p and miRNA 133-3p in formaline fixed paraffine embedded (FFPE) tissue samples of EC patients and compared the relative differences by considering prognostic factors.
Materials and Methods: This study includes 49 patients with type 1 EC (1.patient group), 35 patients with type 2 EC (2.patient group) which had surgical staging with a diagnosis of EC and 45 patients undergone endometrial sampling for abnormal uterine bleeding (control group) in our clinic between January 2010–December 2014. Expression levels of selected miRNAs were evaluated by qRT-PCR. Then, the prognostic variables of disease were compared with the levels of their expression. Kolmogorov Smirnov, Mann Whitney U, Kruskal Wallis and Dunn tests were used for statistical analysis. A p value below 0,05 was accepted as significant.
Results: miRNA 204-5p expression levels were significantly increased in type 1 EC patients comparing to control and type 2 EC groups (p=0,017 and 0,001 respectively). miRNA 138-5p and 133-3p expression levels were significantly increased in type 1 and type 2 EC patients comparing to control group (p=0,001). But, there were no significant correlation between expression levels and prognostic variables of EC.
Conclusion: This is the first study evaluating the levels of miRNA 138-5p expression in ECs. Our results suggest that these miRNAs might be oncomiRNAs in the molecular pathogenesis of EC.
KEY WORDS: MicroRNA, Endometrium Cancer, Biomarker
14:15 – 14:30 Mr. Yaman AlAhmad College of Medicine, Qatar University, Qatar
Yaman Farid Alahmad was admitted at Qatar University (QU) in 2014, initially as
an Engineering student. By the end of 2014, Yaman transferred and joined the first
batch of the College of Medicine of QU. During his first year at the College of
Medicine, Yaman showed a great interest in medical research. Thus, he joined Dr.
Al Moustafa’s lab where he started his research.
THE 7TH ANNUAL MEETING OF THE MEACR – GAZIANTEP. TURKEY 28
Role of cell phone radiofrequency in head and neck cancer
progression Yaman AlAhmad1,2, Mohamed Badie Ahmed1, Mohammed Aljaber1 & Ala-Eddin Al Moustafa1,2,3 1College of Medicine & 2Biomedical Research Centre, Qatar University, Doha, Qatar; Correspondence should be addressed to Ala-Eddin Al Moustafa E-mail: [email protected]; [email protected] 3Oncology Department, McGill University, Montreal, Quebec, Canada
Head and Neck (HN) malignancies are frequent cancers worldwide. These cancers are characterized by a marked propensity for local invasion and lymph node metastases. The etiology of HN cancers are affected by several factors comprising gene mutations, environmental factors in addition to life style. On the other hand, cell-phones are now in widespread practice and it has been suggested that their use maybe linked to an increased risk of human brain and probably HN cancers. However, the outcome of cell-phone radiofrequency (RF) on HN cancer progression has not been identified yet. Thus, in our lab, we explored the effect of cell-phone RF on HN cancer progression using two models, chorioallantoic membrane (CAM) of the chicken embryo which is the most common model for angiogenesis and two human oral cancer cell lines, SCC9 and FaDu. Our data revealed that cell-phone RF promotes angiogenesis of the CAM of the embryo at seven days of incubation. Meanwhile, we found that cell-phone RF can enhance cell motility and invasion of SCC9 and FaDu cells; this is accompanied by a down-regulation of E-cadherin, which is a major key controller of cell invasion and metastasis. Regarding the mechanism of cell-phone RF on angiogenesis and cell invasion, our study showed that cell-phone RF activate Erk1/Erk2 in our cell line models. This investigation suggests that cell phone RF enhances HN cancer by stimulating angiogenesis and cell invasion via, at least, Erk1/Erk2 activation. Thus, our data imply that cell-phone use in HN cancer patients could have a dramatic effect on their cancer progression
14:30 – 14:45 Prof. Ala-Eddin Al Moustafa College of Medicine, Qatar University, Qatar
Ala-Eddin Al Moustafa has earned his B.Sc. from Aleppo University (Aleppo-Syria)
and his Master as well as PhD in Developmental Biology from Paris XIII University
(Paris-France). Afterwards, he completed his training as a postdoctoral fellow at
McGill University (Montreal-Canada). He was then appointed as a project director
and an assistant professor at the Lady Davis Institute and the Oncology
Department of McGill University, respectively. Dr. Al Moustafa and his Colleagues
from Aleppo University established the first Cancer Research Centre in Aleppo-Syria
within the Syrian Society Against Cancer. He also founded the Middle-Eastern
Association for Cancer Research and its journal, the Clinical Cancer Investigation
Journal. Dr. Al Moustafa published more than eighty papers, in international
journals, and book chapters. His main research focuses on the roles of several
Oncogenes and Onco-viruses in human carcinogenesis and metastasis. In May
2015, Dr. Al Moustafa joined the College of Medicine of Qatar University.
THE 7TH ANNUAL MEETING OF THE MEACR – GAZIANTEP. TURKEY 29
Src/Abl tyrosine kinase inhibitor is a promising molecule for
human papillomavirus-positive cervical cancer therapy Ala-Eddin Al Moustafa1,2,3
1College of Medicine & 2Biomedical Research Centre, Doha, Qatar; 3Oncology Department/McGill University, Montreal, Quebec, Canada E-mails: [email protected]; [email protected]
Cervical cancer is the second most common malignancy in women worldwide. Infection by high-risk human papillomaviruses (HPVs) is the main cause of human cervical cancer. Alternatively, aberrant activation of the non-receptor tyrosine kinases Src and c-Abl contributes to the progression of several human cancers; in addition, it is well-known that EGF-receptor activities are elevated in human carcinomas, including cervical, and are often associated with aggressive cancer. In this study, we compared the effects of SKI-606 with Iressa, Src/Abl and EGF-R kinase inhibitors, respectively, on selected parameters in HeLa and SiHa cervical cancer cell lines, which express E6/E7 onco-proteins of high-risk HPV types 18 and 16, respectively. We reported that SKI-606 and Iressa inhibit cell proliferation and deregulate cell cycle progression in both cell lines. In parallel, we found that SKI-606 induces differentiation to an epithelial phenotype “mesenchymal-epithelial transition”; consequently, SKI-606 causes a dramatic reduction in cell motility and invasion abilities of HeLa and SiHa cancer cells, in comparison with untreated cells and Iressa-treated cells in which these parameters are only slightly affected. These changes are accompanied by a regulation of the expression patterns of E-cadherin and catenins; additionally, SKI-606 clearly down-regulates the expression of P-cadherin, fascin, Id-1, IGF-R1 and EGF-R which are important controllers of cancer invasion and metastasis. The molecular pathway analysis of Src/Abl inhibitor demonstrated that SKI-606 inhibits the phosphorylation activity of -catenin and consequently converts its role from a transcriptional regulator to a cell-cell adhesion molecule. Our data indicate that SKI-606 disturb signaling pathways involved in regulating tumor progression genes via catenin alteration, suggesting that Src/Abl inhibitor, in comparison with EGF-R, is a promising therapeutic agent for human cervical cancer.
Session Chairs: Dr. Mir Faeq Ali Quadri & Dr. Ala-Eddin Al Moustafa
15:30 – 15:45 Prof. Waleed Arafat Faculty of Medicine, Alexandria University, Alexandria,
Egypt
Dr. Arafat obtained his Doctoral and postdoctoral degree and training from the University of Alabama at Birmingham (UAB). He then did a postdoctoral fellowship at St. Jude Children’s Hospital (2003-2004) after which he was a visiting professor at MD Anderson Cancer Institute in 2005. Today Dr. Arafat is professor at the Clinical Oncology Department, Faculty of Medicine, Alexandria University.
Dr. Arafat is a member. Dr. Arafat is a member of several professional national and international associations, including The American Society of Gene Therapy, American Society of Therapeutic radiation & Oncology, American Association of Cancer Research, Society of Clinical Oncology, Egyptian Society
THE 7TH ANNUAL MEETING OF THE MEACR – GAZIANTEP. TURKEY 30
of Cancer, Egyptian Society of Clinical Oncology and Nuclear Medicine, European society of medical Oncology.
Dr. Arafat has over 68 publications in international journals and conferences covering basic science and clinical research. Publications have reached 1040 citations and achieving h-index of 15.
A novel predictive marker of resistance to neoadjuvant
Chemoradiotherapy in young Rectal Cancer patients
W. Arafat, 5 H. Morsy1, A. Gaballah2, M. Samir3, M. Shamseya4, H. Mahrous1, A. Ghazal2, M. Hashish1
1Human Genetics Department, Medical Research Institute, Alexandria, Egypt; 2Microbiology Department, Medical Research Institute, Alexandria, Egypt; 3 Clinical and Experimental Surgery Department, Medical Research Institute, Alexandria, Egypt; 4Clinical and Experimental Internal Medicine Department, Medical Research Institute, Alexandria, Egypt; 5Clinical Oncology and Nuclear Medicine Department, Faculty of Medicine, Alexandria University.
Objectives: The aim of the study was to delineate the gene expression profile of LGR5 in rectal
cancer (RC) tissues among young Egyptian patients. The study aimed at investigating the
possible link between this cancer stem cells (CSCs) related gene and clinical outcome, including
response to neoadjuvant chemo-radiotherapy (CRT).
Methods: The study was conducted on 30 young Egyptian RC patients, who were
recommended to undergo neoadjuvant CRT. Paired tumor and non-tumor adjacent mucosal
tissues were obtained from patients by routine biopsy techniques. Total RNA was extracted
followed by reverse transcription, then quantitative PCR was performed using SYBR green.
Expression levels of several CSCs related gene including LGR5 in tumor relative to adjacent non-
tumor tissues were calculated using the comparative Cq method after normalization for the
expression of ACTB. Patients were followed up for assessment of response to neoadjuvant CRT
based on revised RECIST 1.1.
Results: Among CSCs genes that are tested, only Overexpression of LGR5 in human RC tissues
compared to non- tumor tissues was detected. Furthermore, correlation analysis showed that
higher expression of LGR5 was correlated with more depth of tumor invasion, LN metastasis,
advanced cTNM stage and mesorectal fascia involvement. On the other hand, it was not
correlated with gender, age, tumor site nor pathological features. These results suggest that
LGR5 may not only play an important role in the progression of RC but also serve as a potential
unfavorable prognostic biomarker for RC. In addition, high LGR5 expression level was
associated with poor response to CRT.
ROC curve analysis showed that LGR5 expression is an excellent predictor for response to
neoadjuvant therapy.
Conclusions:
1- High LGR5 expression is, most likely, indicative of poor prognosis among young Egyptian RC
patients.
2- LGR5 expression level is proposed to be a novel predictive marker of resistance to
neoadjuvant CRT in young Egyptian RC patients.
THE 7TH ANNUAL MEETING OF THE MEACR – GAZIANTEP. TURKEY 31
15:45 – 16:00 Dr. Havva Yeşil Çınkır Faculty of Medicine, Gaziantep University, Turkey
Dr. Çınkır obtained her degree from Hacettepe University Faculty of Medicine in 2006, then she specialized in internal medicine at Cukurova University, and became a specialist in medical oncology from Ankara Dr. Abdurrahman Yurtaslan Oncology Training and Research Hospital in 2015. Dr. Çınkır is currently an assistant professor at Gaziantep University’s Faculty of Medicine.
The Role of GA-68 PSMA PET / CT in
Evaluating Response to Docetaxel Therapy
in Castration Resistant Prostate Cancer
Patients Havva Yeşil Çınkır1, Umut Elboğa2, Ertan Şahin2, Y. Zeki Çelen2
1Gaziantep University Faculty of Medicine, Medical Oncology, Gaziantep
2Gaziantep University Faculty of Medicine, Nuclear Medicine, Gaziantep
İntroduction: The first treatment option for advanced stage prostate cancer is to stop the
action of androgens in the body, either medically or surgically. The testosterone levels at the
castration level refer to the definition of castration-resistant prostate cancer (CRPC) when PSA
is elevated or new metastases develop. In this case, the chemotherapy regimen containing
docetaxel is usually first tried. Anatomic imaging methods and bone scintigraphy are
inadequate to evaluate the response to docetaxel. In this study, the contribution of Ga-68
PSMA PET / CT in assessing response to docetaxel treatment was investigated.
Methods: We performed Ga-68 PSMA PET / CT imaging in 24 patients with CRPC before
docetaxel treatment. Patients with all metastatic disease were treated 4-6 times with
docetaxel. Patient control Ga-68 PSMA PET / CT imaging was performed to evaluate the
response to treatment. Pre- and post-treatment involvement areas were assessed
semiquantitatively and anatomically, as well as visual assessment, when necessary, with SUV
measurement.
Results: In pre-treatment Ga-68 PSMA PET / CT, pelvic lymph node metastases in 14 patients,
distant lymphatic metastases in 18 patients, skeletal system metastases in 18 patients and
visceral organ metastases in 6 patients were detected in 14 patients as well as intensive
prostate loops in all patients. In the post-treatment evaluation, 16 (66%) of 24 patients were
evaluated as progress disease by monitoring the number, size and Ga-68 PSMA involvement or
new lesions developed in existing lesions. One of the other eight patients had stable disease
and seven had minimal or partial regression.
Conclusion: Ga-68 PSMA is a superior imaging technique for prostate cancer because it
demonstrates the presence of active tumor tissue in PET / CT and allows the possibility to
detect unexpected areas of involvement with whole body imaging. In addition, intensive PSMA
expression in cells in the involvement area helps evaluate the alternative treatment option with
the Lu-177-labeled PSMA molecule in addition to the newer treatments such as abiraterone /
THE 7TH ANNUAL MEETING OF THE MEACR – GAZIANTEP. TURKEY 32
prednisolone, enzalutamide, cabazitaxel and Ra-223 in patients who do not respond to
Docetaxel.
Key words: Prostate, Docetaxel, Ga-68 PSMA PET / CT
16:00 – 16:15 Dr. Ahmad H. Ibrahim Faculty of Sciences, Zakho University, Iraq
Dr. Ahmad obtained his Bachelor of Science degree in Biology, from the University of Baghdad. He subsequently studied at the University of Science Malaysia. Where he obtained his MSc in Cellular and Molecular Biology in 2010. He obtained his Ph.D. in 2014-2015 in Molecular Pharmacology during that time; where he cloned and characterized several genes such as the RNA Helicase gene. Then he started his research at Eman Biodiscovery, School of Pharmaceutical Sciences, and University of Science Malaysia (USM). He later on moved from transcriptional studies to cell signalling, molecular immunology, immunohistochemistry and molecular pharmacology of neurodegeneration disease and neuroprotection sciences at the School of advance Medicine and Dental Sciences at USM. He learned about molecular biology and molecular medicine to the benefits of understanding the molecular basis in human health and drug discovery
.
Neuroprotective efficacy of Cocos nucifera Oil on Mammalian
Cells after Serum Deprivation Chemotactic Grading Oxidative
Stress in The Hypoxia and Ischemia Ailments Ahmad H. Ibrahim1, Ghanem Muhsin Jaafar2, Mohammed Sadeq Al-Ibrahim2, Aman Shah Abdul Majid3 and Amin
Malik Shah Abdul Majid4
1Faculty of Sciences, University of Zakho, Zakho, Kurdistan Region, Iraq; 2Technical Institute of Zakho, Duhok
Polytechnic University (DPU), Duhok, Kurdistan Region, Iraq.3 Pharmacology, Quest International University, Perak,
Malaysia; 4Pharmacology, School of Pharmaceutical Sciences, University of Science Malaysia Pinang, Malaysia.
Email: [email protected]
Introduction: Neurodegenerative diseases can be characterized by progressive neuronal loss
and dysfunction of the nervous system. In optic neuropathies, hypoxia, ischaemia, and
inflammation induce neurodegenerative changes initiated by acute or chronic intermittent
insults including oxidative damage. Current neuroprotection strategies aim to minimize cellular
damage as a result of these processes. Active phytochemicals present in Cocos nucifera oil
extract mixture of active compounds of Polar fatty acid namely Lauric acid, Myristic acid, and
Palmitic acids were utilized.
Objectives: This study aims to evaluate the neuroprotective efficacy of a commercially
developed Fermented Oil, derived from Cocos nucifera.
Methodology: Fermented Oil was screened for its neurotoxic properties on Mammalian Cells,
Retinal Ganglion Cells.
THE 7TH ANNUAL MEETING OF THE MEACR – GAZIANTEP. TURKEY 33
Results: In vitro ischaemia studies revealed 3.1 µg/ml to 50 µg/ml was most effective in rescuing
Retinal Ganglion Cells. Cells from the detrimental effect of: 1) 48hr serum deprivation and 2)
24hr chemical hypoxia exposure of 300 µM cobalt (II) chloride (CoCl2).
Conclusion: FCO thus exhibits its neuroprotective activities by inhibiting ischaemic and hypoxic
in Retinal Ganglion Cells and 2) neutralizing free radicals of Cocos nucifera oil extract mixture
of active compounds of Polar fatty acid namely Lauric acid which constitutes 46.6 %, 21.8 % of
Myristic acid and Palmitic acid 11.5 % were originate.
Keywords: Neuroprotection; Ischaemia, Hypoxia, Retinal Ganglion Cell; and Fermented Cocos nucifera oil.
16:15 – 16:30 Dr. Hale Çolakoğlu Er Faculty of Medicine, Gaziantep University, Turkey
She graduated from University of Gaziantep, School of Medicine with third degree in 2007 . She worked as assistant doctor at Pharmacology Department of Gazi University between December 2007- March 2008. She completed her specialty education at Radiology Department of Ankara University School of Medicine between the years of 2008-2013. She started public service obligation at Gaziantep Şehitkamil State Hospital as a radiology specialist. She worked at State hospital between July 2013 - May 2016. She is an assistant professor in Radiology Department at University of Gaziantep since June 2016. She has several articles, almost all of which were published in SCI-E indexed national or international journals. She is interested in all subjects of diagnostic radiology.
Efficacy of 64 detector computed tomography for the
preoperative staging and resectability evaluation of
pancreatic premalignant and malignant masses Bengi Sarı1, Hale Çolakoğlu Er2, Serdar Akyar3
1 Ankara University, MD, School of Medicine, Department of Radiology, Ankara, Turkey
2 University of Gaziantep, MD, Assistant professor, School of Medicine, Department of Radiology, Gaziantep,
Turkey
3Ankara University, MD, Professor,School of Medicine, Department of Radiology, Ankara, Turkey
Objective: To evaluate the efficacy of a 64 detector CT for preoperative staging and to evaluate
the resectability of malignant and premalignant lesions in patients with pancreatic tumors.
Methods: Patients were included in the current study if they were referred to Ankara University
radiology department between November 2010 and April 2013 for 64 detector CT for the
preoperative staging of suspected pancreatic cancer; further, included patients had a
histopathologically confirmed diagnosis of pancreatic malignant or premalign tumor following
surgery. Twenty-four consecutive patients (12 men and 12 women with a mean age of 53.6
±12years (24–72 years)) who met the aforementioned inclusion criteria were included in this
study.
THE 7TH ANNUAL MEETING OF THE MEACR – GAZIANTEP. TURKEY 34
Results: 46% of 24 patients with malignant pancreatic masses were determined to be localized
(17% Stage 1A, 29% Stage 1B), 50% were locally invasive (12.5% Stage 2A, 37.5% Stage 2B),
and 4% were unresectable (Stage 3). The accuracy rates for T1, T2, T3, and T4 were 100%, 95%,
91%, and 95%, respectively. The sensitivity rates for T1, T2, T3, and T4 were calculated as 100%,
100%, 83%, and 100%, respectively. The specificity rates for T1, T2, T3, and T4 were calculated
as 100%, 94%, 100%, and 95%, respectively. The accuracy, sensitivity, specificity rates in lymph
node staging were 75%, 50%, and 92%, respectively. The accuracy and specificity rates for M
staging were 75% and 92%, respectively. The accuracy, sensitivity, and specificity rates for the
evaluation of preoperative resectability were 91%, 100%, and 91%, respectively.
Conclusion: 64 detector CT is an important method for the diagnosis of and for the
preoperative staging of pancreatic masses.
16:30 – 16:45 Dr. Murat Karaoglan Faculty of Medicine, Gaziantep University, Turkey
I am Murat Karaoğlan. Born 1969 in Gaziantep. Studies of Medicine at the University of Ege (1987-1994); Assistant at the University of Gaziantep Faculty of Medicine, Department of Pediatric(1994-2000); Work experience: I worked as pediatrician between 2000-2011. Vice Head of Gaziantep Children Hospital at 2002-2006. I worked as pediatrician at 2006-2011 at Gaziantep Children Hospital. Assistant at the University of Gaziantep Faculty of Medicine, Division of Pediatric Endocrinology (2011-2014) I worked as Pediatric Endocrinologist between 2014-2017 in Gaziantep Dr. Ersin Arslan Training and Research Hospital. I have been working as Assistant Professor in Division of Pediatric Endocrinology of Gaziantep University Faculty of Medicine since October 2017.
Main fields of interest: Preocious puberty, multiple endocin neoplasia, sex differentiation disorder
From hyperglycemia to hypoglycemia: A Case of Children with
Nesidioblastosis Murat Karaoglan1, Mehmet Keskin1, Emel Aytaç1, Bülent Hayri Özokutan2
1 Gaziantep University, Faculty of Medicine, Department of Pediatric Endocrinology
2 Gaziantep University, Faculty of Medicine, Departmnet of Pediatric Surgery
Abstract: Nesidioblastoma is uncommon, insulin secreting, pancreatic neuroendocrin tumor.
The ductal epithelium differentiates into defective pancreatic βcell, lead to severe, long-
standing hypoglycemia due to hyperinsulinism. It is rarely seem in adolescent. We present a 16-
year-old girl who presented with a diagnosis of metabolic syndrome at the time of first
admission and was diagnosed with nesidioblastosis.
Case Report: A 16-year-old girl presented with complaints and findings of obesity, hirsutism,
menstrual irregularity, low and high blood sugar values measured randomly since eight
months. In her medical history, both hyperglycemia and hypoglycemia were found in the
follow-up of the intermittent blood glucose measurements. On physical examination, Tension
arterial was measured 140/90 mm / Hg. There is widespread hair growth in percentage and
THE 7TH ANNUAL MEETING OF THE MEACR – GAZIANTEP. TURKEY 35
androgen sensitive areas. She was morbidly obese. She had common acanthosis nigricans.
Adrenal CT and pituitary MR were normal. blood glucose values were often higher than 200 mg
/ dL. The patient was diagnosed with metabolic syndrome. occasional hypoglycemia was
accepted as reactive hypoglycaemia.In the past month, however, the patient's hypoglycemia
has become more symptomatic and frequent. Especially after the meal, hypoglycaemic
episodes were evident.
The patient underwent radial echoendoscopy. A hypoechoic nodule with a size of 16 * 14 mm
was found in the pancreas. Of 70% panceras was removed by distal pancreotectomy. Pancreatic
tissue pathology was found to be compatible with nesidioblastosis (Figure 1). Blood sugar was
stable for a short time. After two months, severe hypoglycaemia occured again. Total
pancreatectomy was performed after 6 months. After pancreatoctomy, she had type 1
diabetes.
Discussion: The diagnosis of nesidioblastosis, which is very rare in adolescents and adults, is
very difficult. There are no specific diagnostic methods. Imaging methods provide insufficient
information. Intraarterial calcium stimulation test or somatatin receptor scintigraphy is not
very useful and is often not diagnostic method. The differential diagnosis from insulinoma is
difficult. However, postprandial hypoglycemia may be clinically helpful in differential diagnosis
for diagnosis of nesidioblastosis. Open surgery is mandatory for definite diagnosis and
treatment algorithms. The amount of pancreotectomy is still controversial.
Result: Nesidioblastosis is a very rare cause of hyperinsulinemic hypoglycemia in adults. It is
usually associated with gastric surgery or with insulinoma. The association with the
hyperglycemia such as the metabolic syndrome and type 2 diabetes, is extremely rare.
Therefore, we suggest that in the presence of hypoglycemia in patients with hyperglycemia in
adolescence, it should not be forgotten.
16:45 – 17:00 Dr. Shamal Abduallah Al Muffti Faculty of Sciences, University of Duhok, Iraq
Dr. Al Muffti obtained bachelors degree in plant protection from the University of
Mosul, Iraq in 1981. He went on to study toxicology for his masters, and then
obtained his PhD in molecular biology from the University of Baghdad in 2009. Dr.
Muffti completed his post doctorate training in molecular biology at the College of
Agriculture and natural Resources, of the University of Michigan at the USA.
Dr. Al Muffti is currently the head of the biology department of the Duhok
University, Duhok, Iraq.
Dr. Muffti participated in several national and international conferences and
workshops, and he has more than 20 publications in national and international
journals.
THE 7TH ANNUAL MEETING OF THE MEACR – GAZIANTEP. TURKEY 36
The Impact of Antiapoptotic and Angiogenesis
activity of Fermented Virgin Coconut Oil (FVCO) as
protecting Agent for neurodegeneration disease Ahmad H. Ibrahim1, Shamal Abdulah Mohamad Saeed Al_Muffti2 and Amin Malik Shah Abdul Majid3
1Faculty of Sciences, University of Zakho, Zakho, Kurdistan Region, Iraq.2Faculty of Sciences, University of
Duhok, Duhok, Kurdistan Region, Iraq.3Pharmacology, School of Pharmaceutical Sciences, University of Science
Malaysia Pinang, Malaysia. Email: [email protected]
Introduction: The science of Pharmacology and toxicology provides a broad overview of the
chemicals that have the potential to produce adverse health effects. In our
previous communications, we reported that Fermented Virgin Coconut Oil FVCO possessed
a broad spectrum of proliferative and antioxidant activities. The FVCO is meticulously
extracted through bacteria fermentation process yielding up to 45% extraordinarily pure
lauric acid. Lauric acid is a fatty acid having 12 carbon chains (C12) which is a fat-soluble
organic compound. Objectives: This study was designed to evaluate the FVCO is able to
reduce cell death of retinal ganglion cells (RGC-5) caused by serum deprivation.
Moreover, to show the efficacy of FVCO in promoting angiogenesis for wound healing
application using both in-vitro and in-vivo assays. Methodology Cells were subjected to
serum deprivation and then were treated by using FVCO at different concentrations from
(6-200µg/ml).Various procedures were used to demonstrate the effect of FVCO such as
resazurin fluorescent dye assay, cells morphology, and apoptosis assay. Angiogenesis for
wound healing application using both in-vitro and in-vivo assays. Angiogenesis activity was
assessed by cell migration analysis of human umbilical vein endothelial cells (HUVEC),
microvessel formation using rat aorta ring assay (RARA) and VEGF activity in HUVECs.
Results: The results of this study show that FVCO decreases apoptotic cell death induced by
serum deprivation and significantly increases neuronal viability. Additionally, FVCO
significantly showed stimulation growth of the new blood vessels, stimulated cell migration
at (12.5-25µg/ml). Conclusion: This result exhibits that FVCO acts as a potent wound
healing activity by modulating angiogenesis via upregulation of VEGF, and a good candidate
as a supplement for nerodegeneration disease.
Keywords; ANTIAPOPTOTIC; Angiogenesis; Fermented virgin coconut oil
THE 7TH ANNUAL MEETING OF THE MEACR – GAZIANTEP, UNIVERSITY 37
POSTER PRESENTATIONS
1. Elaeagnus Angustifolia: A promising medicinal
plant for oral cancer therapy
Islam Mohamed1, Ahmed A. Mohamed1, Mennatallah Abdelkader1, Alaaeldin I. Saleh1 & Ala-
Eddin Al Moustafa1,2,3
1College of Medicine & 2Biomedical Research Centre, Qatar University, Doha, Qatar; 3Oncology Department, McGill University, Montreal, Quebec, Canada. E-mail: [email protected]; [email protected]
Introduction: Elaeagnus angustifolia (EA) is a medicinal plant that has been used for centuries in treating many human diseases, in the Middle East, including fever, amoebic dysentery, gastrointestinal problems (1,2). However, the effect of EA plant extract on human cancer progression especially oral malignancy has not been investigated yet. Thus, first we examined the effect of EA flower extract on angiogenesis in ovo, and on selected parameters in human oral cancer cells. Materials and methods: Chorioallantoic membranes (CAMs) of chicken embryos at 3-
7 days of incubation were used to assess the effect EA flower plant extract on
angiogenesis (3). Meanwhile, cell proliferation, soft agar, cell cycle, cell invasion and cell
wounding assays were performed to explore the outcome of EA plant extract on FaDu
and SCC25 oral cancer cell lines. On the other hand, western blot analysis was carried
out to evaluate E-cadherin and Erk1/Erk2 expression and activation, respectively, in
FaDu and SCC25 under the effect of EA extract.
Results: Our data show that EA extract inhibits cell proliferation and colony formation, in addition to the initiation of S cell cycle arrest and reduction of G1/G2 phases. In parallel, EA extract provokes differentiation to an epithelial phenotype “mesenchymal-epithelial transition: MET” which is the opposite of “epithelial-mesenchymal transition, EMT”: an important event in cell invasion and metastasis (4). Thus, EA extract causes a dramatic decrease in cell motility and invasion abilities of FaDu and SCC25 cancer cells in comparison with their controls. These changes are accompanied by an up-regulation of E-cadherin expression. The molecular pathway analysis of the EA flower extract reveals that it can inhibit the phosphorylation of Erk1/Erk2, which could be behind the inhibition of angiogenesis, the initiation of MET event and the overexpression of E-cadherin. Conclusions: Our findings indicate that EA plant extract can downgrade human oral
cancer progression by the inhibition of angiogenesis and cell invasion via Erk1/Erk2
signaling pathways.
THE 7TH ANNUAL MEETING OF THE MEACR – GAZIANTEP, UNIVERSITY 38
2. Vitamin D and Cancer
Ayhan Vurmaz, Sefa Çelik
Afyon Kocatepe University, Faculty of Medicine, Medical Biochemistry Department, Ali
Çetinkaya Campus, 03200-Afyonkarahisar/TURKEY
Vitamin D refers to a group of steroid-like molecules containing cholecalciferol,
ergocalciferol, calcidol and calcitriol. There are two important forms for humans,
ergocalciferol (Vitamin D2) and cholecalciferol (Vitamin D3). While Vitamin D2 is
produced by plants, Vitamin D3 is synthesized from 7-dehydrocholesterol by
exposure to UV radiation in the skin. After being activated in the kidneys, it is
transported through the Vitamin D-Binding Protein (VDBP) to the vitamin D
receptor positive tissues. VDR is a member of the nuclear receptor family, which
includes estrogen receptor, progesterone receptor, androgen receptor. Calcitriol
regulates up to 200 genes directly or indirectly. The inhibitory effect of vitamin D
on angiogenesis, metastasis and invasion, and inflammation reduction,
stimulation of differentiation, apoptotic and antiproliferation activity are
regulated by transcriptional regulation. Vitamin D has a wide range of actions in
many types of cancer. Since most cell lines available for in vitro investigations are
cancer cell lines, studies on the mechanical effects of vitamin D 1, 25 (OH) 2D3 or
analogs are based on the effects of cancer in cancer cells. This makes it difficult to
determine the precise cellular mechanisms that vitamin D may have in cancer
prevention. However, when vitamin D is reported to inhibit angiogenesis,
metastasis, and invasion, vitamin D may play a more specific role in cancer
treatment. Epidemiological studies have shown that there is a high risk of cancer
with low levels of Vitamin D and a relationship between diet and cancer, according
to these studies. The World Health Organization (WHO) states that colon cancer is
associated with vitamin D deficiency. A prospective meta-analysis also revealed an
inverse relationship between serum 25-OHD levels and breast cancer risk in
postmenopausal women. In addition, it alleviates the damaging effects of cancer
by regulating specific signaling pathways in the breast, colon and the similar
tissues.
Key words: Vitamin D, Cancer
3. New cancer treatment strategy: Endoplasmic
reticulum stress
Sefa Çelik, Ayhan Vurmaz
Afyon Kocatepe University, Faculty of Medicine, Medical Biochemistry Department, Ali
Çetinkaya Campus, 03200-Afyonkarahisar/TURKEY
THE 7TH ANNUAL MEETING OF THE MEACR – GAZIANTEP, UNIVERSITY 39
Endoplasmic reticulum (ER) is the main organelle responsible for multiple cellular functions such as protein folding and maintenance of cellular homeostasis. ER stress is activated by a variety of factors and triggers an unfolded protein response (UPR) that either reverts homeostasis or activates cell death. Multiple studies have clarified the link between ER stress and cancer and the role of UPR in particularly. UPR is one of the mechanisms of resistance to cancer treatment, as it regulates the paradoxical microenvironment of cancer. In tumor cells, ER stress may correct homeostasis, and neighboring circulation may provide hospitality for tumor survival and tumor enlargement. During tumor formation, high proliferation rates of cancer cells require increased ER protein folding, assembly, and transplantation, conditions that can induce physiological ER stress. ER stress response is accepted as a cytoprotective and it participates in adaptation to tumor growth and challenging circles. Three ER stress signaling branches localized in ER, inositol requiring enzyme 1α (IRE1α), activating transcription factor 6 (ATF6) and pancreatic ER kinase-like ER kinase (PERK) are involved in tumorigenesis. IRE1α and its down-signaling X-box binding protein (XBP1) contribute to cancer progression. XBP1 is increased in many human cancers such as breast cancer, hepatocellular carcinoma and pancreatic adenocarcinoma. Similarly, another ER stress-related branche PERK/eukaryotic initiation factor 2α (eIF2α)/ATF4 also contributes to cancer progression. The regulation/inhibition of ER chaperones or an arm of the UPR components such as ATF4, XBP1 and PERK has recently been proposed as potential cancer treatments. The accumulation of evidence helps to elucidate the role of ER stress response in tumor development and cancer resistance. Findings from the researches have increased the exciting possibility of targeting UPR components in cancer treatment and can facilitate exploration of the different roles of UPR branches that can produce survival or death signals in tumorigenesis. Key words: Endoplasmic reticulum stress, cancer therapy, unfolded protein response
4. Envitonmental pollutants linked with an increased
risk of cancer in humans
Sefa Çelik, Ayhan Vurmaz, Buğra Koca, Ahmet Kahraman
Afyon Kocatepe University, Faculty of Medicine, Medical Biochemistry Department, Ali
Çetinkaya Campus, 03200-Afyonkarahisar/TURKEY
It has been known that several environmental pollutants are definitely associated
with an increased risk of cancer in humans. In residental life, an increased risk of
mesothelioma has been reported among individuals exposed to asbestos. Many
studies have reported an increased risk of lung cancer due to outdoor air pollution.
Based on the results of the studies, the rate of lung cancer attributable to urban air
pollution in Europe can be as high as 10.7%. A causal relationship has been
established between tobacco use and lung cancer, which may account for 1.6% of
lung cancers. Radon is another source of carcinogens in closed air that can account
for 4.5% of lung cancers. The increased risk for bladder may be due to water
THE 7TH ANNUAL MEETING OF THE MEACR – GAZIANTEP, UNIVERSITY 40
chlorination by products. Exposure to other environmental pollutants, including
pesticides, dioxins and electromagnetic fields, makes available evidence about
cancer risk less satisfactory. In humans, inorganic arsenic in drinking waters plays
an important role in the formation of bladder, skin and lung cancers. Interestingly
several pesticides used in the past have been shown to cause cancers in
experimental animals. The fact that most pollutant-derived cancers arise in the
lungs gives a special perspective to the problem as most of these cancers occur in
smokers and these risk factors can be eliminated.
5. FUNGAL LARYNGITIS: REPORT OF 5 CASES
Ayşe Nur Akatlı1, Hasan Gökçe1, Emine Şamdancı1, Tuğba Bayındır2, Yüksel Toplu2
1 Department of Pathology, İnönü University Faculty of Medicine Malatya, TURKEY
2 Department of Otorhinolaryngology, İnönü University Faculty of Medicine Malatya, TURKEY
Fungal infections of the larynx are considered to be associated with the
immunocompromised patients who are on long-term corticosteroid therapy, or have
chronic systemic diseases, or have undergone organ transplantation, which depends on
immunologic suppression. Clinical similarity to more common lesions like leukoplakia
and carcinoma can cause confusion because fungal laryngitis is an uncommon
condition in immunocompetent patients.
It is important to identify the lesion earlier for the accurate treatment. Diagnosis is made by the demonstration of fungal spores, hyphae or pseudohyphae on tissue biopsy. Demonstration of epithelial hyperplasia with hyperkeratosis, and intraepithelial neutrophils on biopsy should prompt the pathologists to search for fungus by using specialized stains.
We report a series of 5 cases on laryngeal fungal infections diagnosed as candidiasis or aspergillosis, who had a history of smoking and a common initial complaint of hoarseness. Pathologists and clinicians should be aware of fungal laryngitis because they can mimick lesions such as cancer or leukoplakia.
6. Effect of Apoptosis of Calcium Malic Acid Complex
Gökhan CEYHAN1,2, 3*, Bilge ALLI4, Ebru URAS4, Akif Hakan KURT2,3,4
*Corresponding author’s e-mail: [email protected]
1 Kahramanmaraş Sütçü İmam University, Vocational School of Technical Science, Food
Technology, Kahramanmaraş¸ Turkey
2 Kahramanmaraş Sütçü İmam University, Research and Development Centre for
University-Industry-Public Relations, Kahramanmaraş¸ Turkey
3 Kahramanmaraş Sütçü İmam University, Faculty of Medical, Department of
Pharmacology,
Kahramanmaraş, Turkey
THE 7TH ANNUAL MEETING OF THE MEACR – GAZIANTEP, UNIVERSITY 41
4 Kahramanmaraş Sütçü İmam University, Institute of Natural and Applied Sciences
Department of Bioengineering and Sciences, Kahramanmaraş, Turkey
Introduction/Aim: Out of use in beverages and foods are health benefits large
malic acids. In pharmaceutical preparations, L-malic acid can be used to treat
hypertension, low immunity, liver failure and other diseases. However, there is no
data on the effect of Malic acide on colon cancer cell proliferation and apoptosis.
The present study aimed to our synthesized MCa.2H2O2 complexes analyze the
anticancer effects of the on HT-29 colon cancer cells.
Materials and Methods: In this study, new Calcium complex it was extracted by
sumach and characterized by spectroscopic and analytical methods was Ca(II)
complex is pentadentate complex. Molecular structures of the Ca(II) complex was
determined by single crystals X-ray diffraction study. The status of cancer cell line
viability was determined by MTT assay. HT-29 colon cancer cell was treated with
various concentrations (10, 50, 100, 250, 500 µM) of MCa complex in 96-well plates
and incubated for 72 h. Following incubation, MTT solution was added to each well
at a concentration of 0.5 mg/ml, and incubated for 4 h at 37°C. At the end of this
period, 100 µl DMSO solvent was added to each well. The absorbance values at 570
nm of the solution in each well were read using a spectrophotometer.
Results: The results revealed that MCa significantly decreased cell proliferation. In
addition to the antiproliferative effect of MCa, a marked increase in apoptotic
activity was observed when cells were treated with 500 µM MCa complex.
Conclusion: These findings indicate that the new Calcium complex is able to exert
antiproliferative and proapoptotic effects on HT-29 cells.
Key words: Malic acid, Apoptosis, HT-29, Proliferative
7. Differential expression of immunological
markers after anti-PD-1 (Nivolumab) treatment
in a patient with squamous cell carcinoma
Mohammed Ussama Al Homsi1, Maysaloun Merhi1, 2, Afsheen Raza1, 2, Varghese Philipose
Inchakalody1, 2, Abdulqadir Jeprel Japer Nashwan1, 2, Niloofar Allahverdi1, 2, Roopesh
Krishnankutty3, Gianfranco Pittari1, 2, Shahab Uddin3, Abdul Rehman Zar Gul1, Karl Richard
Alexander Knuth1, 2 and Said Dermime1, 2
1National Center for Cancer Care and Research, Hamad Medical Corporation, Doha, Qatar
2Translational Cancer Research Facility and Clinical Trial Unit, Interim Translational Research
Institute, Hamad Medical Corporation, Doha, Qatar
3Interim Translational Research Institute, Hamad Medical Corporation, Doha, Qatar
Background: PD-1/PD-L1 checkpoint inhibition has been shown to enhance T cell-
mediated anti-tumor activity, but clinical responses are invariably confined to a fraction
THE 7TH ANNUAL MEETING OF THE MEACR – GAZIANTEP, UNIVERSITY 42
of treated patients. Enriching responding cohorts based on biomarkers of response is a
tempting strategy to improve the clinical outcome of PD-1/PD-L1 blockade. To date,
however, response biomarkers offering binary discrimination of responsiveness have
not yet emerged. NY-ESO-1 is a cancer-testis antigen aberrantly expressed in a variety
of human cancers, known to trigger potent humoral and cellular immune responses. In
this study, we correlated clinical responsiveness to PD-1/PD-L1 blockade and natural
immunity to NY-ESO-1 in a patient with recurrent squamous cell carcinoma (SCC) of
the head and neck. This data has been generated to support the notion, that presence
anti-NY-ESO-1 integrated immunity may potentially identify response to checkpoint
blockade in SCC patients.
Methods: A 71-year-old Qatari male patient was first diagnosed with SCC in 1997. After
initial chemo-radiation, a recurring SCC involving the supraglottic region and tongue
base was identified in 2016. Second-line treatment with Nivolumab, a monoclonal
antibody against PD-1, was started (3 mg/kg every 2 weeks for 5 cycles). Peripheral
blood samples were obtained before Nivolumab and after the 3rd and the 5th cycles of
Nivolumab. A panel of 27 plasma biomarkers was carried out by multiplex analysis. The
antibody response to the NY-ESO-1 antigen was measured in the plasma using ELISA
and Western Blot assays against the NY-ESO-1 protein. The cellular response to the
NY-ESO-1 antigen was investigated in patient’s PBMCs using an ELISPOT assay for IFN-
gamma production by T cells against the NY-ESO-1 protein.
Results: Clinical response to Nivolumab; After the 5th cycle of Nivolumab treatment,
the patient’s bleeding stopped and CT scan follow-up showed stable disease, no
progression or distant metastasis. Determination of anti-tumor immune response; In
the following results we compared data obtained after vs. before Nivolumab treatment.
The cytokine/lymphokine profile data showed that 6 biomarkers were significantly
increased after the 3rd cycle: IL-6 (*p=0.02), IL-8 (*p=0.015), IL-10 (**p=0.007), GM-
CSF (*p=0.014), IFN-γ (***p=0.0006) and TNF-α (**p=0.03). 4 biomarkers were
significantly increased also after the 5th cycle: IL-6 (*p=0.01), IL-10 (*p=0.02), sCD137
(**p=0.04) and IL-1β (*p=0.04). 5 biomarkers were significantly decreased after the 3rd
cycle: Granzyme A (*p=0.01), Granzyme B (**p=0.004), Perforin (*p=0.01), sFAS
(**p=0.005) and IL-17A (*p=0.013). 3 biomarkers were significantly decreased also after
the 5th cycle: Granzyme A (*p=0.03), Granzyme B (**p=0.002), Perforin (**p=0.005),
and IL-17A (*p=0.017). The remaining 13 biomarkers analyzed (IL-2, IL-4, IL-5, IL-7, IL-
12 (p70), IL-13, IL-21, IL-23, MIP-1α, MIP-3α, MIP-1β, ITAC and sFASL) showed no
significant change. ELISA results showed that the NY-ESO-1 antibody titers were
significantly higher before treatment (***p=0.0002) and after treatment (3rd cycle
***p=0.0018; 5th cycle ***p=0.002) compared to healthy control. Interestingly,
Western Blot analysis demonstrated a significant reduction of such responses after
treatment (5th cycle **p=0.0032) and this may be due to tumor shrinkage as indicated
by CT scan examination which showed stable disease. ELISpot results demonstrated
that IFN-γ secretion was significantly increased after the 3rd cycle (*p=0.02) with higher
IFN-γ secretion after the 5th cycle (*p=0.03) of anti-PD-1 treatment.
THE 7TH ANNUAL MEETING OF THE MEACR – GAZIANTEP, UNIVERSITY 43
Conclusion: We have studied the expression of immunological markers before and
after anti-PD-1 treatment in a patient with long and recurrent history of head and neck
SCC and spontaneous immunity to NY-ESO-1. This patient showed a transient
regression and stability of the tumor after anti-PD-1 treatment. The study of
immunological markers in this patient showed a differential expression before and after
anti-PD-1 treatment. We conclude that this immunological monitoring would help in
providing critical understanding of the predictive value of NY-ESO-1 antibody and T cell
response and their upstream and/or downstream cytokines/lymphokines cascade as
biomarkers of response to such treatment.
8. In vitro induction of NY-ESO-1 tumor antigen
expression in lung cancer cells after treatment with 5-
Aza-2'-Deoxycytidine and X-irradiation Varghese Philipose Inchakalody1, 2, Sara Taleb1, 2, Maysaloun Merhi1, 2, Roopesh
Krishnankutty3, Lubna Therachiyil3, Afsheen Raza1, 2, Shahab Uddin3, Alexander Knuth1,
2, Said Dermime1, 2
1National Center for Cancer Care & Research, Hamad Medical Corporation, Doha, Qatar
2Translational Cancer Research Facility, Interim Translational Research Institute, Hamad
Medical Corporation, Doha, Qatar
3Interim Translational Research Institute, Hamad Medical Corporation, Doha, Qatar
Background: The capability of the immune system to recognize and kill cancer
cells is dependent on many factors, with the expression of immunogenic target
antigens in cancer cells being one of the prime mechanisms. The NY-ESO-1
antigen is the most immunogenic cancer testis (CT) antigens known to date.
Generally, it is not expressed in normal adult tissues, except in germ cells. The NY-
ESO-1 expression at the cellular level is often heterogeneous depending on the
methylation of the NY-ESO-1 gene. It has been reported that the
chemotherapeutic drug 5-aza-2'-deoxycytidine (5-aza-CdR) enhances the
expression of NY-ESO-1 protein through demethylation of promoter CpG islands.
Radiotherapy is known, on the other hand, to induce de novo protein synthesis
which enhances the expression of NY-ESO-1 protein in cancer cells. We
hypothesized that 5-aza-CdR and radiotherapy would both in vitro induce the NY-
ESO-1 protein in lung cancer cell lines.
Methods: Two lung cancer cell lines (NCI-H522, NCI-H1975) were cultured in the
presence of 5-aza-CdR or X-irradiation and screened for NY-ESO-1 expression. For
5-aza-CdR treatment, 2.5x105 cells were cultured under standard conditions. The
cells were treated with increasing concentrations of 5-aza-CdR (2.5 to 10 μM) for
48 hrs. After treatment, cells were further incubated for 72 hrs. For X-irradiation,
2x106 cells were cultured under standard conditions. The cells were exposed to a
30 Gy dose of X-Rays using RAD source irradiator. After treatment, cells were
THE 7TH ANNUAL MEETING OF THE MEACR – GAZIANTEP, UNIVERSITY 44
further incubated for 72 hrs. The treated cells were analyzed for NY-ESO-1 protein
expression using a cellular ELISA assay. In this, a cell density of 4 x 104/ well were
seeded in a 96-well flat bottom plate and incubated overnight. Cells were then
fixed, blocked and permeabilized. NY-ESO-1 protein expression was detected
using the primary anti-NY-ESO-1 antibody and goat anti-human-HRP as
secondary antibody. The cell lysates from treated samples were further analyzed
by Western Blotting using chemiluminescence. NY-ESO-1 protein bands were
detected using the primary anti-NY-ESO-1 antibody and goat anti-human
antibody as secondary antibody. In addition, a proteomic profiling of the 5-aza-
CdR treated NCI-H1975 was also carried out using label-free mass spectrometry-
based comparative proteomics approach.
Results: Among the lung cancer cell lines (NCI-H522, NCI-H1975), NCI-H522
showed constitutive expression of NY- ESO-1 protein before treatment. Cellular
ELISA resulted in a dose-dependent increase of NY-ESO-1 expression in both cell
lines after 5-aza-CdR treatment: NCI-H522 and NCI-H1975 had the highest
expression (~2-fold and 16-fold respectively) when treated with the highest
concentration (10μM). Using Western Blot analysis, we detected a band of NY-
ESO-1 protein at 18 kDa in both cell lines after treatment with 5-aza-CdR. X-
irradiation resulted in a 2-fold increase in the expression of NY-ESO-1 in both cell
lines. Comparative proteomics profiling of the 5-aza-CdR treated vs. untreated
cells identified a number of proteins with differential expression and their
functions are being analyzed using functional annotation (DAVID) analysis.
Conclusion: Our data demonstrated that treatment of lung cancer cells with either
5-aza-CdR or X-irradiation resulted in an increase in the expression of NY-ESO-1
tumor antigen. This suggests that the treatment with 5-aza-CdR or X-irradiation
will induce and amplify the expression of NY-ESO-1 in lung cancer cells leading to
a better stimulation of T- cells against this immunogenic antigen. Potential use of
such therapy would be a novel strategy for the treatment of NY-ESO-1 associated
lung cancers.
9. Blocking of PD-1 protein enhances functional
activity of Viral specific T cells generated for
the treatment of viral infections after
allogeneic hematopoietic stem cell
transplantation
Maysaloun Merhi1, 2, Mohammad Bakr1, Ibrahim Al-Hijji1, Gianfranco Pittari1, 2, Munir Jalis1,
2, Shahab Uddin3, Alexander Knuth1, 2, Said Dermime1, 2
1National Center for Cancer Care & Research, Hamad Medical Corporation, Doha, Qatar
THE 7TH ANNUAL MEETING OF THE MEACR – GAZIANTEP, UNIVERSITY 45
2Translational Cancer Research Facility, Interim Translational Research Institute, Hamad
Medical Corporation, Doha, Qatar
3Interim Translational Research Institute, Hamad Medical Corporation, Doha, Qatar
Background: Viral infection represents a major cause of disease and mortality after
allogeneic hematopoietic stem cell transplantation (AHSCT) for hematologic
malignancies. It has been shown that adoptive transfer of specific T cells generated
against virus-associated antigens is capable of treating infections that are resistant to
conventional therapies. We have standardized a rapid, cost-effective and highly
efficient protocol for expanding virus-specific T cells (VSTs). These expanded VSTs
showed high specificity to the most immunodominant viral antigens. Although these
VSTs were shown to possess prominent levels of cytotoxic and effector markers, they
also expressed the programmed cell death protein (PD-1). PD-1 is an immune-inhibitory
receptor expressed on the surface of T cells and it is known to induce T cells exhaustion
and inactivation and this may lead to the ineffectiveness of such VSTs after infusion in
patients receiving AHSCT. To this end, we have used an anti-PD-1 antibody to block this
molecule during the expansion of such VSTs and analyzed the effect of this treatment
on T cells phenotype and functional activity.
Methods: Peripheral blood mononuclear cells (PBMCs) were isolated from buffy coats
of 3 healthy donors (D1, D2 and D3). To expand VSTs, PBMCs were stimulated in G-Rex-
10 flasks with a Master Pepmix containing a pool of 11 overlapping peptides libraries
spanning Epstein Barr virus (EBV), Adenovirus (AdV), Cytomegalovirus (CMV),
Polyomavirus (BKV) and Human Herpes virus (HHV6) antigens in the presence of two
cytokines, IL-4 and IL-7. To investigate the effect of anti-PD-1 treatment, we have
selected one of our healthy donors (D1). Therefore, PBMCs were isolated from D1
peripheral blood and 4 G-Rex-10 flasks were prepared and cultured with the same
cytokines and viral Pepmix as above. 3 flasks received one dose of the anti-PD-1
antibody (1μg/ml) one time at days 2, 5 or 8 and the remaining flask was not treated.
All the VSTs were collected at day 11. We used an ELISpot assay to measure IFN-γ
production by T cells after challenge with the Master Pepmix as well as the individual 11
Pepmix antigens. Flow cytometry analysis was used to phenotype these VSTs. Cells
proliferation and cytotoxicity were determined using BrdU incorporation and Calcein
AM assay respectively.
Results: 3 VST cell lines were generated after 11 days of culture with an expansion
power of 9-folds (9x106 to 77x106 cells) for D1, 11-folds (12x106 to 133x106 cells) for D2
and 7-folds (11x106 to 79x106 cells) for D3. These VSTs produced specific IFN-γ to most
of the viral antigens (7/11 antigens for D1 and 10/11 antigens for D2 and D3) and showed
high proliferative and cytotoxic activities to the viral peptides. Expanded VSTs were
CD3+ T cells (98±0.5%) in which CD4+ T cells were dominant (64±9%). Importantly, they
were mostly of the central memory cell population (CD45RO+ CD62L+; 73±2%).
However, these VSTs expressed high levels of the PD-1 antigen (48±14%). Interestingly,
VSTs treated with anti-PD-1 showed differential expression of phenotypic markers and
functional activity only after treatment at day 5: IFN-γ secretion against the Pepmix was
THE 7TH ANNUAL MEETING OF THE MEACR – GAZIANTEP, UNIVERSITY 46
significantly decreased (***p=0.0008); there was a 1.2-fold increase in the CD4+ T cells
and a 2-folds decrease in the CD8+ T cells; The percentage of naïve CD45RA+ T cells
was decreased by 4-folds; PD-1 expression was increased in both central CD45RO+
CD62L+ and effector CD45RO+ CD62L- memory T cells (1.5 and 1.7-folds respectively),
whereas, PD-1 expression was declined by 2-folds in the CD8+ T cells. Importantly, the
expression of T cells cytotoxicity (CD107) and activation (CD278) markers were
increased after anti-PD-1 treatment (2 and 1.7 folds respectively). This indicates that
the PD-1 molecule was induced by day 5 of VSTs expansion and using anti-PD-1 at that
time modulated the VSTs phenotype and activity.
Conclusions: We have standardized an in vitro protocol for rapid expansion of VST cell
lines with anti-viral specificity to the most immunodominant viral antigens expressed
by viruses causing infection after AHSCT. These VSTs were shown to highly express the
T cells negative regulator PD-1 antigen that induces T cells exhaustion and inactivation.
A preferential expression of both phenotypic and functional T cells markers was
recorded in these VSTs after treatment with anti-PD-1 antibody at day 5 of T cell
expansion. Our findings demonstrated that blocking PD-1 on VSTs would improve the
cytotoxicity and activation of these T cells and help to reverse T cells
exhaustion/dysfunction leading to a long-lasting specific antiviral activity in patients
undergoing AHSCT. Further investigations are being carried out to confirm these
results.
10. The Diagnostic Role Of Caveolin, Hmgb1 And
Endocan Levels In Non-Small Cell Lung Cancer
(Group Of Basic And Clinical Research)
Hülya Çiçek1, Gülper Nacarkahya2, Hasan Ulusal1, Aykut Bahçeci3, Havva Yeşil Çınkır4,
Necla Dirier5, Füsun Tuşgül2, Zeliha Yıldırım2, Özlem Nuray Sever6, Dinç Süren7, Vildan
Kaya8, Ömer Aydın Yıldırım9, Nuri Orhan10, Burak Bilgin11, Aslan Güzel12, Mustafa
Erdoğan13, Mustafa Yıldırım14
1Gaziantep University Faculty of Medicine, Biochemistry, Gaziantep
2Gaziantep University Faculty of Medicine, Medical Biology and Genetics, Gaziantep
3Dr. Ersin Arslan Training and Research Hospital, Medical Oncology, Gaziantep
4Gaziantep University Faculty of Medicine, Medical Oncology, Gaziantep
5Sanko University, Pharmacology, Gaziantep
6Medical Oncology, Gaziantep
7Antalya Training and Research Hospital, Pathology, Antalya
8Medstar Antalya Hospital, Radiation Oncology, Antalya
9Medicalpark Hospital, Internal Medicine, Gaziantep
10Medicalpark Hospital, Biochemistry, Gaziantep
11Medicalpark Hospital, Ophthalmology, Gaziantep
12Medicalpark Hospital, Brain and Neurosurgery, Gaziantep
13Medicalpark Hospital, Cardiovascular Surgery, Gaziantep
14Medicalpark Hospital, Medical Oncology, Gaziantep
THE 7TH ANNUAL MEETING OF THE MEACR – GAZIANTEP, UNIVERSITY 47
Introduction: Lung cancer is the leading cause of cancer-related deaths. There are
two basic histological types of lung cancer, small cell lung cancer (SCLC) and non-
small cell lung cancer (SCLC). NSCLC accounts for 80-85% of all cases. Despite
improvements in treatment, the prognosis of the disease is poor. Due to the fact
that the prognosis is bad, intensive researches continue for early diagnosis and
treatment. Caveolae are invaginations of the plasma membrane in 50 to 100 nm
omega form, which act as regulators of signal transduction.
Caveolins are a class of oligomeric structural proteins that are both necessary and
sufficient for caveolae formation. Interestingly, caveolin-1 is involved in oncogenic
cell transformation, tumorigenesis and metastasis pathogenesis.
High mobility group box (HMGB) proteins are non-histone nuclear proteins with
very different functions in the cell. There is increasing evidence for the role of
HMGB1 in cancer progression, angiogenesis, invasion and development of
metastases. Studies suggest that HMGB1 may have an important role in cancer
development.
Endocan, previously termed endothelial cell-specific molecule-1, is a 50 kDa
soluble proteoglycan consisting of a mature polypeptide of 165 amino acids and a
single dermatan sulfate chain covalently linked to the serine residue at position
137. Expressed in vascular endothelium, this dermatan sulfate proteoglycan is
freely circulating in the bloodstream of healthy individuals. Recently, Endocan
mRNA levels have been recognized as one of the most important molecular
signatures that cause poor prognosis in various types of cancer, including lung
cancer.
In our study, the diagnostic role of Caveolin, Hmgb1 and Endocan levels measured
in serum for small cell lung cancer was investigated.
Materials And Methods: In the Medicalpark Gaziantep Hospital Medical Oncology
Clinic, between 2014 and 2017, patients diagnosed with small-cell carcinoma
diagnosed as histopathologically confirmed and healthy volunteers were included
in the study. Patient files were scanned and information such as age, gender,
routine laboratory tests were obtained retrospectively. Blood samples remaining
from the blood samples of patients for routine checks were collected prospectively
directly before the start of first-line systemic chemotherapy. They were
centrifuged for 15 min at 1,000g within 1 hr of collection. The resulting sera were
aliquoted into microtubes and either immediately frozen at -80 C. These samples
were taken to the refrigerator at 4 ° C temperature overnight before
measurements were taken. Serum samples were allowed to stand at room
temperature for 2 hours before being run by the ELISA method. The samples were
then subjected to measurement procedures with mixing using vortex. Caveolin,
Hmgb1 and Endocan serum levels were investigated using Elisa method.
Statistical analyses were performed using SPSS for Windows 15.0 software. The
normal distribution suitability of the interchanges was examined using visual
THE 7TH ANNUAL MEETING OF THE MEACR – GAZIANTEP, UNIVERSITY 48
(histogram and probability plots) and analytical directions (Kolmogorov-Smirnov /
Shapiro-Wilk tests). In the Kolmogorov-Smirnov test, cases, where the p-value was
above 0.05, were found as the normal distribution. When normal distribution was
not determined, the patient and control group were compared using the Mann-
Whitney U test.
Results : A total of 42 participants were enrolled in the study, 19 (45.2%) patients
and 23 (54.8%) healthy volunteers. Caveolin was found in the patient group as 48.3
± 84.1 (Range 5.5-250) ng / ml, Hmgb1 3.15 ± 3.14 (Range 0.08-12.18) ng / ml and
Endocan 250.7 ± 180.5 (Range 36.2-789.6) ng / L. In the control group, caveolin was
determined as 26.4 ± 38.9 (Range 3.46-176.8) ng / ml, Hmgb1 2.98 ± 2.79 (Range
0.39-8.83) ng / ml and Endocan 301.2 ± 174.6 (Range 109.8-722.6) ng / L. Since
caveolin levels did not show a normal distribution, the patient and control group
were compared using the Mann-Whitney U test. There was no statistically
significant difference between the patient and control groups in terms of caveolin
levels (p = 0.471). Since Hmgb1 levels did not show a normal distribution, the
patient and control group were compared using the Mann-Whitney U test. No
statistically significant difference was found between the patient and control
group in terms of Hmgb1 levels (p = 0.919). Since Endocan showed no normal
distribution, the patient and control group were compared using the Mann-
Whitney U test. No statistically significant difference was found between patient
and control group in terms of Endocan levels (p = 0.283).
Discussion: In our study, no correlation was found between caveolin, Hmgb1 and
Endocan levels and small extracellular carcinoma measured in serum.
Nevertheless, we think that the search for a new marker for early diagnosis and
treatment of this disease, which is common in the community, should be
continued.
Key Words: Caveolin, Endocan, Hmgb1, Lung Carcinoma
11. The Diagnostic Role Of Caveolin, Hmgb1 And
Endocan Levels In Colon Carcinoma: (Group
Of Basic And Clinical Research)
Hülya Çiçek1, Gülper Nacarkahya2, Hasan Ulusal1, Aykut Bahçeci3, Havva Yeşil Çınkır4, Necla
Dirier5, Füsun Tuşgül2, Zeliha Yıldırım2, Özlem Nuray Sever6, Dinç Süren7, Vildan Kaya8, Ömer
Aydın Yıldırım9, Nuri Orhan10, Burak Bilgin11, Aslan Güzel12, Mustafa Erdoğan13, Mustafa
Yıldırım14
1Gaziantep University Faculty of Medicine, Biochemistry, Gaziantep
2Gaziantep University Faculty of Medicine, Medical Biology and Genetics, Gaziantep
3Dr. Ersin Arslan Training and Research Hospital, Medical Oncology, Gaziantep
4Gaziantep University Faculty of Medicine, Medical Oncology, Gaziantep
5Sanko University, Pharmacology, Gaziantep
THE 7TH ANNUAL MEETING OF THE MEACR – GAZIANTEP, UNIVERSITY 49
6Medical Oncology, Gaziantep
7Antalya Training and Research Hospital, Pathology, Antalya
8Medstar Antalya Hospital, Radiation Oncology, Antalya
9Medicalpark Hospital, Internal Medicine, Gaziantep
10Medicalpark Hospital, Biochemistry, Gaziantep
11Medicalpark Hospital, Ophthalmology, Gaziantep
12Medicalpark Hospital, Brain and Neurosurgery, Gaziantep
13Medicalpark Hospital, Cardiovascular Surgery, Gaziantep
14Medicalpark Hospital, Medical Oncology, Gaziantep
Presenter: Havva Yeşil Çınkır
Introduction: Colon cancer is the third most common cancer among all cancers in
terms of both frequency and cancer-related deaths. According to 2006 data, the
incidence in Turkey is second in women and fifth in men. Colonoscopy and fecal occult
blood test are used as diagnostic tools in the early diagnosis of colon cancer. In addition
to these diagnostic tools, studies of serum marker development are maintain their
popularity.
Caveolins are a class of oligomeric structural proteins that are both necessary and
sufficient for caveolae formation. Interestingly, caveolin-1 has been implicated in the
pathogenesis of oncogenic cell transformation, tumorigenesis, and metastasis.
Caveolae are plasma membrane specializations that contain the structural proteins
caveolins, and appear to be important for normal signal transduction. The caveolin
scaffolding domain interacts with several signaling molecules, sequestering them in the
absence of activating signals and thereby reducing the signal-to-noise ratio. Deletion
and mutation of genes that encode caveolins are implicated in the pathogenesis of
several human diseases. Down-regulation of caveolin-1 protein expression leads to
deregulated signaling and consequently tumorigenesis.
High mobility group box (HMGB) proteins are non-histone nuclear proteins that have
very different functions in the cell. The evidence is increasing that HMGB1 plays a key
role in cancer progression, angiogenesis, invasion and metastasis. Studies suggest that
HMGB1 may have an important role in cancer development.
Endocan, previously termed endothelial cell-specific molecule-1 is a 50 kDa soluble
proteoglycan composed of a mature polypeptide of 165 amino acids and a single
dermatan sulfate chain covalently linked to the serine residue at position 137. This
dermatan sulfate, proteoglycan is freely circulating in the bloodstream of healthy
individuals and expressed in vascular endothelium. Experimental evidence suggests
that endocan is a key player in the regulation of major processes such as cell adhesion,
inflammatory disorders and tumor progression.
In this study, we investigated the diagnostic role of Caveolin, HMGB1 and Endocan
levels that measured in serum for colon cancer.
THE 7TH ANNUAL MEETING OF THE MEACR – GAZIANTEP, UNIVERSITY 50
Materials And Methods: Patients diagnosed with histopathologically confirmed
colorectal cancer in the Medicalpark Gaziantep Hospital Medical Oncology Clinic
between 2014 and 2017 years and healthy volunteers were included in the study.
Patient files were screened and information such as age, gender, routine laboratory
tests were obtained retrospectively.
Blood samples were collected prospectively directly prior to the start of systemic
chemotherapy. They were centrifuged for 15 min at 1,000g within 1 hr of collection. The
resulting sera were aliquoted into microtubes and either immediately frozen at -80 0C.
These samples were placed in the refrigerator at 4 0C temperature one night before the
measurements.
The serum samples were allowed to rest at room temperature for 2 hours before
working with the ELISA method. Later, measurement procedures were implemented
by mixing the samples using vortex. All concentration/absorption graphic curves of
research parameters such as Caveolin, HMGB1 and Endocan and calculations on the
results were conducted on a program of the device Biotek_ELx808 (Winooski, Vermont,
ABD).
Statistical analyses were performed using SPSS for Windows 15.0 software.
Conformance of the variables to the normal distribution was analyzed using visual
(histogram and probability graphics) analytic methods (Kolmogorov-Smirnov/Shapiro-
Wilk tests). In the Kolmogorov-Smirnov test, cases, where the p-value was above 0.05,
was accepted as the normal distribution. Groups were compared using the Mann-
Whitney U test when normal distribution was not determined. Results were
represented as the mean ± standard deviation.
Results: A total of 53 participants were included in the study, 30(56.6%) patients and
23(43.4%) healthy volunteers. Caveolin was determined as 58.5±106.2 (Range 0.80-
411.8) ng / ml, HMGB1 3.47±5.31 (Range 0.11-26.03) ng / ml and Endocan 307.5±269.2
(Range 74.2-1203.2) ng / L in the patient group. In the control group, caveolin was
determined as 26.4±38.9 (Range 3.46-176.8) ng / ml, HMGB1 2.98±2.79 (Range 0.39-
28.83) ng / ml and Endocan 301.2±174.6 (Range 109.8-722.6) ng / L.
The patient and control groups were compared using the Mann-Whitney U test because
of caveolin levels were not normally distributed. There was no statistically significant
difference between the patient and control groups in terms of caveolin levels (p =
0.971).
Since HMGB1 levels did not have the normal distribution, the patient and control
groups were compared using the Mann-Whitney U test. There was no statistically
significant difference between patient and control group in terms of HMGB1 levels (p =
0.936).
THE 7TH ANNUAL MEETING OF THE MEACR – GAZIANTEP, UNIVERSITY 51
Since Endocan levels did not have the normal distribution, the patient and control
group were compared using the Mann-Whitney U test. There was no statistically
significant difference between the patient and control groups in terms of endocan
levels (p = 0.355).
Discussion: In our study, no correlation was found between serum caveolin, HMGB1
and endocan levels and colorectal cancer. However, we think that the search for a new
marker should be continued in the case of this common disease in the society.
Key Words: Caveolin, Colon carcinoma, Endocan, Hmgb1
12. Expression Analysis of PBRM1 and BAP1 Genes in
Prostate Cancer
Rozhgar A. KHAILANY1,2, Naser GILANI1,3, Belan KANABE4, *Kübra OKÇU5, Khandakar
A. S. M. SAADAT1
1Department of Medical Biology and Genetics, Faculty of Medicine, Gaziantep University,
Gaziantep, Turkey; 2Department of Biology, College of Science, Salahaddin University,
Erbil, Iraq; 3Farabi Molecular Diagnostic Laboratory, Erbil, Iraq; 4Department of Biology,
Gaziantep University, Gaziantep, Turkey; 53rd Grade Undergraduate Student, Faculty of
Medicine, Gaziantep University, Gaziantep, Turkey.
Prostate cancer (PC) is the second commonest diagnosed malignancy and the fifth
leading cause of cancer mortality in men, and represents a substantial public
health burden. Etiology of prostate cancer remains largely unknown. Indeed, the
only well-established risk factors to date are age, ethnicity and a family history of
prostate cancer. The goal of this study is to evaluate the expression level of PBRM1
and BAP1 in prostate cancer tissues. PBRM1 gene, a tumor- suppressor gene,
which is encodes the BAF180 protein, a chromatin targeting subunit of a SWI/SNF
chromatin remodeling complex, which is involved in transcriptional activation and
repression of selected genes. PBRM1 acts as a negative regulator of cell
proliferation. BAP1 gene provides instructions for making a protein called ubiquitin
carboxyl-terminal hydrolase BAP1 (shortened to BAP1). This protein functions as
a deubiquitinase, which means it removes a molecule called ubiquitin from certain
proteins. In the current study, PBRM1 and BAP1 of 31 paired tumor and normal
tissue samples that were grouped according to the clinical characteristics of
patients were determined by quantitative real-time polymerase chain reaction
(qRT-PCR) technique. Expression level of PBRM1 and BAP1 were significantly
decreased (down-regulated) in prostate cancer compared to normal tissues.
Consequently, Patients with discordant BAP1 or PBRM1 expression across their
matched primary and metastatic tumors usually showed loss of expression during
progression to metastatic prostate cancer.
key words: Prostate Cancer, PBRM1, BAP1, Expression analysis, qRT-PCR.
THE 7TH ANNUAL MEETING OF THE MEACR – GAZIANTEP, UNIVERSITY 52
13. The effect of smokeless tobacco on oral
cancer in the Middle Eastern and North African region: A systematic review
Mir Faeq Ali Quadri 1; Tenny John 2 and Santosh Kumar Tadakamadla 3
1Course Coordinator, Evidence Based Dentistry, Department of Preventive Dentistry, Jazan
University, Saudi Arabia
2Assistant Professor, Department of Maxillofacial Surgery and Diagnostic Sciences, Jazan
University, Saudi Arabia
3Research Fellow, Menzies Health Institute Queensland, Griffith University, Queensland,
Australia
Introduction: A rate-per-year projection analysis, revealed that the incidence of oral
cancer will be doubled in MENA region by the year 2030.
Aim: To systematically review the literature on the effect of smokeless tobacco on oral
cancer in Middle Eastern and North African region.
Materials and Methods: Reporting of this systematic review comprehend the
Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA)
guidelines. PubMed, Web of Science, Cochrane and CINAHL databases were searched
using organized combinations of MeSH terms and keywords. Only articles
demonstrating relationship of oral cancer with smokeless tobacco or khat were
included. Quality assessment of included articles was performed using Newcastle
Ottawa Score.
Results: Initial search retrieved 87 titles (PubMed = 51, Web of Science = 32, Cochrane
= 0, CINAHL= 4); and 59 remained after removing the duplicates. Ten articles satisfied
the eligibility criteria. Among these, five articles studied the effect of smokeless
tobacco on the occurrence of oral cancer and all reported a greater prevalence of oral
cancer in tobacco users than non-users. One study from Yemen evaluated the effect of
tobacco and khat usage on oral Leukoplakia and reported a dose-dependent
association between use of khat, Shammah on Oral Leukoplakia. None of the studies
received the highest possible stars which demonstrate that they were not of high
quality.
Conclusions: Shammah users are at higher risk of oral cancer than non-users. As the
studies were of low quality which were conducted on small sample sizes, this conclusion
should be interpreted with caution.
Keywords: Oral cancer; Smokeless tobacco; Middle East; Shammah
THE 7TH ANNUAL MEETING OF THE MEACR – GAZIANTEP, UNIVERSITY 53
14. COMMON CAUSES OF POSTMENOPAUSAL
BLEEDING: SINGLE CENTER 5-YEARS EXPERIENCE
Neslihan Bayramoğlu Tepe1, Zehra Bozdağ2, Hüseyin Çağlayan Özcan1, Denizhan
Bayramoğlu3, Aynur Mustafa1
Gaziantep University School of Medicine, Department of Obstetrics and Gynecology
Gaziantep University School of Medicine, Department of Pathology
Gaziantep Av. Cengiz Gökçek Obstetrics and Gynecology Hospital
Aim: In our study, we aimed to classify the common causes of postmenopausal
bleeding (PMB), to determine whether the causes in Western countries differ or
not, and whether there is a change in the etiologic factors of PMB according to
years.
Method: Patients who applied to Gaziantep University Faculty of Medicine,
Department of Obstetrics and Gynecology Clinic between June 2012 and July 2017
with complaints of PMB and who underwent endometrial sampling by dilatation &
curettage (D & C) were included in the study. The patients' ages, pregnancy
numbers, menopausal periods, hormone replacement therapy (HRT), and D & C
results were retrospectively scanned and recorded. The patients' ages, number of
pregnancy, status of menopaus and hormone replacement therapy (HRT), D & C
results were retrospectively scanned and recorded. Patients who had vaginal
bleeding due to cervical lesions were excluded from the study. Patients who had
D&C before the past 2,5 years were grouped as group A and in the 2,5 years were
grouped as group B. Patients were classified as polyp, atrophy, hyperplasia,
endometritis, drug effect, endometrial cancer, myoma, gestational trophoblastic
disease (GTD) and insufficient material according to D & C results.
Results: The mean age of 760 patients taken into the study was 59.65 years (min:
50, max: 90), mean pregnancy numbers were 4.56 (min: 0, max: 12) and mean
menopause duration was 11.83 years (min: 1, max: 43). One hundred and ninety
seven (%25.9) patients were diagnosed as polyp, 148 (%19,5) patients were
atrophy, 99 (%13,02) patients were hyperplasia, 85 (%11,2) patients were
endometritis, 83 (%10,9) patients were endometrial cancer, 67 (%8,8) patients
were drug effect, 2 (%0,3) patients were myoma and 2 (%0,3) patients were GTD.
In 77 (10.1%) patients, pathology was reported as ‘inadequate material’.
In contrast with the rate of malignancy was decreased (A: %13.45, B: %8.19), the
rates of drug effects (A: %7.1, B: %10.6) and hyperplasia (A: %11.92, B: %14.20)
were increased during the last 2,5 years. There was no statistically significant
difference between these results.
Conclusion: Unlike western societies, the most common cause of PMB was polyps
in our community. In recent years, awareness of the community and early
application to the hospital has reduced the frequency of malignancy with
screening programs in the field of health, but the number of patients with HRT and
THE 7TH ANNUAL MEETING OF THE MEACR – GAZIANTEP, UNIVERSITY 54
hyperplasia is increasing. For this reason, sampling with D & C would be
appropriate to exclude possible malignancy with a PMB patient.
Keywords: Endometrial cancer, dilatation, curettage, postmenopausal bleeding.
15. Jordan Cancer Registry (JCR) Data 2010-2014;
Surveillance for Jordan Cancer Burden.
Omar Nimri, MD.
Background: Cancer registry is an important tool for any successful cancer control
program. The cancer related data from Jordan was vague scarcity. This, urged scholars
to set up the first and only population-based cancer registry in Jordan. Which did the
Ministry of health and the Middle East Cancer Consortium_MECC- established it jointly.
The Registry started to collect data from cases of cancer referred to the treatment and
diagnostic facilities throughout the country to improve cancer reporting in the country
and define the size of the cancer problem and the pattern of cancer in Jordan;
distribution of cancer by geographical locations; age; gender; type and cancer sites for
both Jordanians and non-Jordanians.
Methods: The JCR collects cancer data in passive and active methods of case finding,
the collected data coded by means of ICD_O3. Quality control measures applied and
the data stored and computerized using CanReg_4 and CanReg_5; then analyzed
statistically. World standard population for age adjustment and standardization to
facilitate national and international comparison and contrast.
Results: Incidence of the most common cancers among Jordanians, distributed by Site,
Age, Gender, and geographically for the period 2010-2014. The leading cancer among
adults, males was Colorectal (11.9 %) followed by Lung (11.7 %), Leukemia (9.1 %),
Urinary Bladder (8.9 %) and Prostate (8.1 %). While among female cancers are Breast
(34.4 %), Colorectal (9.4 %); Leukemia (6.7 %); Lymphomas (5.8%) and Thyroid (5.3 %).
Childhood cancers were about (4.9%) of all cancers; Leukemia was 1st (34.8 %) followed
by Brain &CNS (20.9%) and Lymphomas (17.5%).
Whereas the most recent mortality data showed lung is responsible for (21.03%) deaths
among males followed by Colorectal (11.0 %) and Leukemia (8.02%). Among females
Breast deaths (26.8%); Colorectal (9.3%) and Leukemia (7.2%).
Conclusion {Use of the data}: Knowledge to action, based on The JCR data, Jordan
started the Jordan Breast Cancer Program for early detection and screening of Breast
Cancer.
THE 7TH ANNUAL MEETING OF THE MEACR – GAZIANTEP, UNIVERSITY 55
16. Tumor-to-Tumor Metastasis: Case Report of Large
Cell Neuroendocrine Carcinoma of Lung,
Metastasizing to Renal Oncocytoma
Metin KARAKOK , Omer Faruk DİZİBUYUK, Zehra BOZDAG
Gaziantep University, Department of Pathology, Gaziantep, Turkey
Distinct metastatic disease within a second primary tumor, tumor-to-tumor
metastasis (TTM), is a very rare phenomenon. Lung cancer metastasis to renal cell
carcinoma represents the most common combination of such TTM. Oncocytoma
can also serve as a recipient site for TTM, and less than 10 cases has been described
in the literature.
A 60-year-old man with a history of large cell neuroendocrine carcinoma of lung
has been operated because of mass in left kidney discovered on PET CT scanning.
On microscopic evaluation, the tumor showed histologically two distinct areas
.There were typical areas of oncocytoma consisted of round to poligonal cells with
abundant densely granular eosinophilic cytoplasm, round uniform nuclei.
Immunohistochemically these cells showed positive reaction with E-cadherin,
CK7, CD15 and EMA. The other tumor adjacent the oncocytoma had a distinctive
morphology was confirmed on subsequent immunohistochemistry. The tumor
consisted of large cells with moderate to abundant cytoplasm and hyperchromatic
nucleus with prominent nucleoli, showed positive reaction with CK7, EMA and
synaptophysin was compatible with large cell neuroendocrine carcinoma.
Although tumor-to-tumor metastasis (TTM) is a rare phenomenon, being aware
of the tumor-to-tumor metastasis phenomenon and considering this possibility is
likely to lead to a correct diagnosis, particularly in patients with a history of a
second malignancy
Key Words: Lung Carcinoma , Oncocytoma, Tumor-to-tumor metastasis,
17. Extragastrointestinal Stromal Tumor of Kidney in
Nontransplant Recipient Patient : The First Case
İn The Literature
Metin KARAKOK1, Omer Faruk DIZIBUYUK1, Ismail KARLIDAG2, Zehra BOZDAG1
1Gaziantep University, Department of Pathology, Gaziantep, Turkey
2 Mehmet Akif Inan Research and Education Hospital, Department of Urology, Sanlıurfa,
Turkey
THE 7TH ANNUAL MEETING OF THE MEACR – GAZIANTEP, UNIVERSITY 56
Gastrointestinal stromal tumors (GISTs) are the most common primary mesenchymal
gastrointestinal neoplasms that is most commonly found in stomach (40–70%), small
intestine (20–40%) and colorectum (5– 15%). It originates from the interstitial Cajal cells
which present throughout the wall of gastrointestinal (GI) tract and coordinate
peristalsism. While the majority of GISTs develop in the GI tract, in rare cases they may
also be found in extragastrointestinal tissues. This type of GIST is known as an
extragastrointestinal stromal tumor (EGIST). The occurrence of most EGIST is related
to the metastasis of primary GIST There have been several reported EGIST cases such
as in mesentery, omentum, retroperitoneum, pleura, lungs, vagina, liver and spleen .
A 58-year-old man, operated because of left renal mass in an external hospital. After
the microscopic examination the tumor diagnosed as malign mesenchymal tumor and
referred to our pathology dapertment for detailed examination and diagnosis. The
microscopic examination of HE sections obtained from paraffin embedded blockes
showed spindle cell neoplasm and immunohistochemical (IHC) examination showed
positive expression with CD117(c-kit), CD-34, Vimentin and Dog-1. Actin expression
was detected in isolated cells. There was no expression with S-100, Desmin, and
Pancytoceratin. Based on the histomorphologic and IHC findings, the tumor was
diagnosed as EGIST.
There was only 3 reported cases in the literature who were all kidney transplant
recipients. To our knowledge, this is the first case reported of EGIST arising in the
kidney which has no history of transplantation.
Key Words: EGIST, GIST, Kidney
18. Collision Tumor of the Stomach: A Case of an
Adenocarcinoma and a Malignant Lymphoma
Metin KARAKOK, Omer Faruk DİZİBUYUK, Zehra BOZDAG
Gaziantep University, Department of Pathology, Gaziantep, Turkey
Adenocarcinoma takes up about 95% among malignant tumors of the stomach,
and the remainings are mostly lymphomas, being less than 5%. The majority of
lymphomas are B cell lymphomas, and the most common types are low-grade B
cell lymphoma of mucosa-associated lymphoid tissue and diffuse large B cell
lymphoma (DLBL) . A collision tumor of the stomach is a rare event. The
occurrence of a collision tumor in the stomach, consisting of adenocarcinoma and
malignant lymphoma, is extremely rare.
A 66-year-old woman with the diagnosis of gastric adenocarcinoma, underwent
total gastrectomy.On macroscopic examination, a polipoid mass with 1 cm
diameter was detected in antrum. The microscopic examination of the mass
THE 7TH ANNUAL MEETING OF THE MEACR – GAZIANTEP, UNIVERSITY 57
revealed two distinct tumor in same area.There were poorly differantiated gastric
adenocarcinoma areas showed positive reaction with Pancytoceratin and EMA,
and the other tumor beside adenocarcinoma consisted of atypical large lymphoid
cells with diffuse growth pattern.These lymphoid cells showed positive reaction
with CD20,CD79a,Bcl-2,Bcl-6,CD10 and MUM-1. Based on this morphologic and
IHC findings, the tumor was diagnosed as a collision tumor consisting of
adenocarcinoma and DLBCL.
In conclusion; all the malignant tumors should be carefully examined for the
second (collision) tumor before the diagnosis.
Key Words: Collision tumor, DLBCL, Gastric adenocarcinoma.
19. Detection of gene expression in sentinel
lymph node of primary breast cancer patients
from Iran
Prof Abolfazl Movafagh1* , Maryam Haji SeyedJavadi 1 , Shahrzad Soleimani2, Narjes
Mehrvar4, Shohreh Alizadeh Shargh3, Neda Mansouri1, Aliasghar Keramatinia4,
Mortazavi-Tabatabaei Seyed Abdol Reza5
1*Department of Medical Genetics, Shohada hospital, Research Center, School of Medicine,
Shahid Beheshti University of Medical Sciences, Tehran, Iran.2 Department of Molecular
Genetics, Institute of Basic Science, Shahrekord Islamic Azad University; 3 Medical
Laboratory Science Department, Midwifery-Nursing Institute, Islamic Azad University of
Chalous Branch, Chalous; 4 Cancer Research Center, Shahid Beheshti University of Medical
Sciences, Tehran; 5 Proteomics Research Center, School of Paramedical Sciences, Shahid
Beheshti University of Medical Sciences, Tehran
Email [email protected]
Background: Sentinel lymph node (SLN) micrometstasis detection improves outcome
for breast cancer follow up procedure. The aim of the present study was to identify gene
profiles that accurately predicted the outcome of breast cancer patients.
Materials and Methods: In this study we examined in 50 Sentinel Lymph Node (SLN)
biopsy present of small number of cancerous cell between breast tumor and Axillary
lymph nodes for the expression of 3 genes MUC1, BUB1b and NEK2 using quantitative-
PCR. Also clinical verification for recurrence to distant organs was performed. Three
gene signature were confirmed based on tumor’s stage, grade, ER status, using
conditional logistic regression.
Results: Based on this findings, the negative reported lymph nodes for metastasis, had
micro metastasis in significant values. There was a significant difference between
normal and cancer samples in 3 gene expression marker and also there was meaningful
THE 7TH ANNUAL MEETING OF THE MEACR – GAZIANTEP, UNIVERSITY 58
relationship between three gene expression with tumor’s grade, stage according to
progression of tumor.
Conclusions: A novel gene expression signature predictive of micro metastatic patients
was evaluated. In this assessment, relationship between these gene with tumor’s
features that finding clear role for these genes with tumor’s outcome, needs to be
established.
Keywords: Breast cancer, Gene signature, Sentinel Lymph node, Iran
20. A case of a male with a sigmoid adenocarcinoma
which accompanied with an isolated unilateral
adrenal metastasis:
Wassim ALMAHLI 1, Ilyas BASKONUS 1, Alper AYTEKIN 1, Latif YILMAZ 1
1: The General Surgery Department, Gaziantep University Hospital, Gaziantep, Turkey.
Although the liver and the lung are the main metastatic sites, the incidence of
adrenal metastasis from colorectal cancer in autopsy ranges from 1.9% to 17.4%
according to different reports.The most common primary tumours that
metastasize to the adrenal glands are the lung,kidney,breast,and rarely the
colorectal cancer.The alone adrenal metastasis due to colorectal carcinoma is very
rare. Due to their rarity, on the basis of international literature and our experience
of adrenalectomy could represent the current“gold-standard”therapeutic
approach. In this report we explain the case of a patient who presented with a
sigmoid cancer, and one side adrenal metastasis without any other different
distant metastasis.The solitary adrenal metastasis of sigmoid cancer is a
comparatively rare condition especially coupled with metachronous contralateral
adrenal metastasis, according to our review of the literature. And it is difficult to
be diagnosed because it doesn't have any characteristic symptoms.
Key words: sigmoid adenocarcinoma-adrenal metastasis-colorectal cancers.
21. The descriptive epidemiology of the Human
papillomavirus attributable cancers: An
international comparison of incidence, and
mortality
Author: Professor Zoubida Zaidi
University of Setif, Algeria
THE 7TH ANNUAL MEETING OF THE MEACR – GAZIANTEP, UNIVERSITY 59
Introduction: Human papillomavirus (HPV) attributable cancers (HPVAC) are a major
worldwide public health concern, with much higher burden in less developed regions.
Cervical cancers represent 530.000 new cases per year and account for the vast majority
of all HPV-attributable cancer cases worldwide. HPV also causes anal, vaginal, vulvar,
penile, and oropharyngeal cancer. Over 90% of the HPV-related ones are related to
HPV16, -18. The HPVAC are dominated by cervical cancer in the developing world,
where cervical cancer screening is limited.
Aim: this communication presents the latest international descriptive epidemiological
data for HPVAC including incidence and mortality in the worldwide.
Methods: the incidence and mortality statistics presented for HPV attributable cancers
worldwide were taken from* the International Agency for Research on Cancer IARC,
the Cancer Incidence in five Continents Vol XI , * GLOBOCAN database, 2012 and the
finding of the Global Burden Diseases study 2015. Data are shown separately for cervix,
other anogenital tract and head and neck cancers
Results: HPVAC represent the second most common infection-related cancers
worldwide with 4,5% of all cancers (630.000 new cancer cases by year) are attributable
to HPV with 8,6% in women and 0,8% in men. Attributable fractions in women ranges
from <3% Australia/New Zealand and the USA to >20% in India and sub-Saharan Africa.
-Cervix accounts for 83% of HPV-attributable cancer, two-thirds of which occur in less
developed countries.
-Other HPV-attributable anogenital cancer includes 8,500 vulva; 12,000 vagina; 35,000
anus (half occurring in men) and 13,000 penis. Anogenital cancers are mainly located in
Latin and Northern America and Australia but a few are also found in Europe and sub-
Saharan Africa. --The head and neck, HPVAC represent 38,000 cases of which 21,000
are oropharyngeal cancers occurring in more developed countries. The incidence of
HPV-attributable head and neck cancer is relatively high over 1.25 per 100,000 are
located in Northern America and Europe.
Conclusions: the preponderant burden of HPV16/18 and the possibility of cross-
protection emphasize the importance of the introduction of more affordable vaccines
in less developed countries.
22. Synthesis of Novel Chalcone Analogs for Triple
Negative Breast Cancer Therapy
Dana Elkhalifa1, Feras Alali1, Ala-Eddin Al Moustafa2,3,4 & Ashraf Khalil1
1College of Pharmacy, 2College of Medicine and 3Biomedical Research Center, Qatar
University, Doha, Qatar; and 4Oncology Department, McGill University, Montréal, Canada
THE 7TH ANNUAL MEETING OF THE MEACR – GAZIANTEP, UNIVERSITY 60
Introduction: Triple negative breast cancers (TNBCs) are aggressive tumors that
do not express human epidermal growth factor receptor 2, estrogen and/or
progesterone receptors. Therefore, TNBC patients have tremendously poorer
prognosis and do not respond satisfactory to current chemotherapeutics.
Chalcone is an attractive molecule for drug synthesis due to its promising
pharmacological activities in a range of diseases including cancer.
Objectives: The aims of this study are to design, synthesize and biologically
evaluate the anticancer activities of novel chalcone-based compounds for the
treatment of triple negative breast cancers.
Methods: Chalcone analogs were synthesized and purified followed by chemical
characterization studies. The molecular anticancer activities were studied in vitro
on noninvasive and invasive breast cancer cell lines. The effect on angiogenesis of
the most promising compounds were studied in vivo using chicken embryos.
Results: Fifteen compounds were synthesized so far. The screening of the first six
compounds (DK1-DK6) revealed that compounds DK2 and DK5 had significantly
inhibited cancer progression. They suppressed colony formation in MCF-7
noninvasive and MDA-MB-231 invasive breast cancer cell lines as was
demonstrated by the soft agar assay. In addition, compound DK5 inhibited
angiogenesis in treated chicken embryos. It had also caused the highest inhibition
of cells proliferation in the MCF-7 cells followed by DK6 at 48 hours posttreatment
(63.1% and 63% inhibition, respectively). The activity of DK5 was significantly
reduced in the MDA-MB-231 cells (34.1% inhibition). In contrast, DK2 caused
significant cells proliferation inhibition (59.8%) in the MDA-MB-231 cell line which
resembles TNBC.
Conclusion: Taken together, our data provided an evidence that some of the
screened compounds (DK1-DK6) may serve as promising therapeutic agents for
TNBCs. The anticancer screening shall be continued and performed for the rest of
the compounds (DK7-DK15).
Gaziantep: The City Gaziantep is one of the oldest continuously
inhabited cities in the world, as traces of
settlement in Gaziantep go back to the 4th
millennium BC. The city fortress, the
Ravanda citadel
is located at the center of the city Gaziantep became the economic
center of the southeastern and east
Turkey. Its industrial area comprises
four percent of the Turkish industry in
general and particularly for olive oil
based soaps and machined carpets.
In addition to several museums in the city, there are various attractions that range from historic
landmarks to shopping centers and entertainment areas. Gaziantep hosts the largest enclosed
shopping centers in the region, Sanko Park, in addition to the Gaziantep Zoo, the home of a
variety of animals and rare birds.
Other important attractions include: The Boyaci Mosque, Sirvani Mosque, Omeriye Mosque,
Eyupoglu Mosque, Kendirli Chruch, Pisirici Kastel (a water fountain built below ground), Tahmis
Coffee House (A coffee house built in 1635-1638 by Mustafa Aga Bin Yusuf) and of course in
addition to the historical bazaars such as Zincirli Bedesten.
8
Gaziantep: Where Old and New intertwine
1. Gaziantep University Tourism Hotel
2. Gaziantep University
3. Gaziantep Citadel
4. Pisirici Kastel
5. Omeriye Mosque
6. Tahmis Coffee House
7. Sanko ParkBayazhan
8. Gaziantep Kent Museum
1
v
2
v
7
3
v
4
v
6
v
5
v
4
v
7
5
6
8
NOTES
NOTES
The 7th annual meeting of the
MEACR was realized thanks to
Gaziantep University in collaboration with the
College of Medicine of
Qatar University